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Abbreviations 
 
4-PBA  sodium 4-phenylbutyrate  
AAV  Adeno-associated virus 
ad  autosomal dominant 
adRP   autosomal dominant retinitis pigmentosa 
adCSNB  autosomal dominant congenital stationary night blindness 
AIF   apoptosis inducing factor 
ar  autosomal recessive 
Arf4  ADP Ribosylation Factor 4  
arRP   autosomal recessive retinitis pigmentosa 
ASAP1 ArfGAP with SH3 Domain Ankyrin Repeat and PH Domain 1 
ATF6   activating transcription factor 6 
BDNF  brain derived neurotrophic factor 
BiP  binding immunoglobulin protein  
Cas9  CRISPR associated protein 9 
CHOP  C/EBP homologous protein 
CNTF  Ciliary neurotrophic factor 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CRX  cone-rod homeobox 
CSNB  congenital stationary night blindness 
DAMPS  damage-associated molecular patterns 
DHA  docosahexaenoic acid 
Drp1   dynamin-related protein 1 
EDEM1 ER degradation-enhancing α-mannosidase-like 1 
EL  extracellular loop 
ER   endoplasmic reticulum  
ERAD  ER associated degradation 
ERG   electroretinogram 
GDNF  glial-derived neurotrophic factor 
GPCR  G-protein coupled receptor 
GRK1  rhodopsin kinase 
gRNA  guide RNA 
HDAC  histone deacetylase 
HDR  homology directed repair 
HSF1  heat shock factor 
HSR  heat shock response 
IFT  intraflagellar transport 
IRD   inherited retinal dystrophy 
IRE1α  inositol-requiring enzyme 1 
IS   inner segment 
KI   knock-in 
KO  knock-out 
LCA   Leber congenital amaurosis 
MAS   magic angle spinning 
Meta II metarhodopsin II 
NHEJ  non-homologous end joining 
NMR   nuclear magnetic resonance  
NRL  neural retinal leucine zipper 
OGG1  8-Oxoguanine glycosylase 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5
ONL  outer nuclear layer 
OS   outer segment 
P  post-natal 
PARP  poly(ADP-ribose) polymerase 
PDE   phosphodiesterase 
PERK  protein kinase RNA-like endoplasmic reticulum kinase 
PSB   protonated Schiff base 
RCS  Royal College of Surgeons  
RdCVF Rod-derived Cone Viability Factor 
RIDD  regulated IRE1-dependent mRNA decay 
RIP   receptor-interacting protein kinases 
ROS  reactive oxygen species 
RP   retinitis pigmentosa 
RPE  retinal pigment epithelium 
RTC   rhodopsin transport carrier 
SD   Sprague Dawley 
TM   transmembrane 
TUDCA tauroursodeoxycholic acid 
UPR  unfolded protein response 
VPA  valproic acid 
WT  wild-type 
VCP  valosin containing protein 
XBP-1  X-box binding protein 1 
XIAP  X-linked inhibitor of apoptosis 
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Glossary 
 
CRISPR/Cas9: a method for specific gene editing that has been developed 
from studying bacterial immunity. The Cas9 nuclease cleaves specific DNA 
sequences based on a guide RNA.  
ERG: the electroretinogram measures the electrical responses of various cell 
types within the retina. The a-wave arises from the photoreceptors and the b-
wave corresponds to the propagation through the retina. A scotopic ERG is 
done in dim light after dark adaptation to measure rod responses, whereas a 
photopic ERG measures cone responses.  
Heat shock response: the cellular response to imbalanced proteostasis in 
the cytoplasm and nucleus.  
Mutation: a change in genomic DNA, and potentially protein, that is 
associated with disease.  
Off-label: the prescription of an approved drug for an indication it has not 
been approved for.  
Outer nuclear layer (ONL): the layer of nuclei outermost in the neural retina, 
corresponding to photoreceptor nuclei. 
Proteostasis: the balance of protein synthesis, modification, traffic and 
degradation that enables function of the proteome and maintenance of protein 
homeostasis.  
Retinitis pigmentosa: an inherited retinal dystrophy, usually characterised by 
rod cell dysfunction and degeneration followed by cone cell dysfunction and 
degeneration.  
Rhodopsin: any opsin + 11-cis-retinal moiety is correctly termed a 
‘rhodopsin’, but here we use the term rhodopsin to refer to the rod opsin + 11-
cis-retinaldehyde photopigment complex of rod cells.   
Schiff Base: the product of the chemical association of an aldehyde with a 
primary amine.  11-cis-retinal forms a Schiff base with rhodopsin via lysine 
296. 
Unfolded protein response: the cellular response to ER stress and 
disturbed proteostasis in the ER. 
Variant: a sequence change in the DNA of unknown significance.  
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Abstract  
Inherited mutations in the rod visual pigment, rhodopsin, cause the 
degenerative blinding condition, retinitis pigmentosa (RP). Over 150 different 
mutations in rhodopsin have been identified and, collectively, they are the 
most common cause of autosomal dominant RP (adRP). Mutations in 
rhodopsin are also associated with dominant congenital stationary night 
blindness (adCSNB) and, less frequently, recessive RP (arRP). Recessive RP 
is usually associated with loss of rhodopsin function, whereas the dominant 
conditions are a consequence of gain of function and/or dominant negative 
activity. The in-depth characterisation of many rhodopsin mutations has 
revealed that there are distinct consequences on the protein structure and 
function associated with different mutations. Here we categorise rhodopsin 
mutations into seven discrete classes; with defects ranging from misfolding 
and disruption of proteostasis, through mislocalisation and disrupted 
intracellular traffic to instability and altered function. Rhodopsin adRP offers a 
unique paradigm to understand how disturbances in photoreceptor 
homeostasis can lead to neuronal cell death. Furthermore, a wide range of 
therapies have been tested in rhodopsin RP, from gene therapy and gene 
editing to pharmacological interventions. The understanding of the disease 
mechanisms associated with rhodopsin RP and the development of targeted 
therapies offer the potential of treatment for this currently untreatable 
neurodegeneration.   
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1.1 Introduction 
The outer retina of the mammalian eye possesses two types of ciliary 
photoreceptor, the rods and cones. Rods, with a peak absorption (λmax) of 
~500 nm, contain the rod-specific rod opsin and are responsible for dim-light 
(scotopic) photoreception. Cones, with a λmax for visible light ranging from 
~350-560 nm, contain one of up to three different cone opsins 
(ultraviolet/violet, middle- and long-wave sensitive). Image-forming 
photoreception is initiated by the absorption of a photon by the vitamin A 
derived chromophore 11-cis-retinal within rhodopsin, causing it to isomerise to 
the all-trans conformation. Whilst any opsin + 11-cis-retinal moiety is correctly 
termed a ‘rhodopsin’, the term rhodopsin is most commonly applied to the rod 
opsin + 11-cis-retinaldehyde photopigment complex (Lythgoe, 1979), and this 
convention will be followed in this review. Rhodopsin is the archetypal G 
protein-coupled receptor (GPCR) with seven transmembrane (TM) α-helices 
(Palczewski et al., 2000). The 11-cis-retinal acts an inverse agonist 
suppressing constitutive activity of the receptor, is located within the pocket 
formed by the α-helices and is coordinated through a protonated Schiff-base 
(PSB) linkage to a lysine residue in the 7th TM domain (K296) (Smith, 2010) 
(Figure 1).  
 
1.1 Identification of mutations in rhodopsin (RHO) 
In the mammalian genome, the ciliary opsin family is composed of the 
rhodopsin gene (RHO); an ultraviolet/violet sensitive opsin gene (OPN1SW);  
middle/long-wave sensitive opsin genes (OPN1MW/LW); and the less well 
characterised opsin 3 (encephalopsin) gene (OPN3). These genes share at 
least three perfectly conserved intronic sites (Bellingham et al., 2003b) and 
appear to have arisen through duplications early in vertebrate evolution 
(Nördstrom et al., 2004). Subsequent to the cloning and characterisation of 
the bovine rhodopsin gene (Nathans and Hogness, 1983), the same authors 
published the structure and sequence of the human orthologue, RHO 
(Nathans and Hogness, 1984). With the exception of the intronless rod opsin 
gene of the Actinopterygii (ray-finned fish) (Bellingham et al., 2003a; 
Fitzgibbon et al., 1995), the RHO gene like all other currently characterised 
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vertebrate rod opsin genes is composed of 5 exons, and the open reading 
frame predicts a 348 amino acid protein with a molecular weight of ~39 kDa. 
 
The RHO gene was initially mapped to the long arm of chromosome 3 at 
3q21-qter (Nathans et al., 1986), and is currently designated at 3q22.1 at 
coordinates 3:129,528,640-129,535,169 (build GRCh38.p10; 
http://www.ensembl.org/). Methodologies used to identify inherited retinal 
dystrophy (IRD) genes have recently been reviewed (Broadgate et al., 2017) 
and causative mutations in the RHO gene were identified by Dryja et al in 
1990 (Dryja et al., 1990b), as the first genetic cause of retinitis pigmentosa 
(RP). The identified nucleotide substitution, c.68C>A, results in the following 
codon change CCC>CAC such that the normally observed proline (CCC) at 
position 23 of the rod opsin protein is substituted by a histidine (CAC) residue 
(p.P23H). Since this discovery, many different RHO mutations have been 
identified and many other genes for RP and other IRDs have been 
discovered, but P23H remains of the most intensively studied causes of IRD. 
Further information regarding the genetic basis of IRDs can be accessed at 
the RetNetTM Retinal Information Network (https://sph.uth.edu/retnet/). 
 
1.2 Phenotypes of rhodopsin associated retinal dystrophies 
Mutations in RHO are associated with a classical form of RP, which is a rod-
cone dystrophy caused by the dysfunction and death of rod cells, followed by 
the dysfunction and death of cone cells. A detailed clinical description of RP is 
beyond the scope of this review and readers are directed to this book chapter 
for more information (Gregory-Evans et al., 2013). Briefly, classical RP is 
characterised by a progressive loss of peripheral vision leading to so-called 
“tunnel vision”. The initial symptom is typically impaired dark adaptation and 
the development of “night blindness” (nyctalopia) through the loss of rod 
function starting in the 1st or 2nd decade of life (Hartong et al., 2006). As 
photoreceptor loss proceeds, there is a loss of pigmentation from the retinal 
pigment epithelium (RPE), and a build-up of intraretinal melanin deposits that 
can assume a “bone spicule” conformation. Central visual acuity is often 
preserved until the end stages of RP. Studies on the prevalence of non-
syndromic RP in different populations indicate a frequency of between 1:3000 
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to 1:5000 individuals (Berson, 1993; Hamel, 2006; Hartong et al., 2006; 
Sharon et al., 2016), with between 15 and 35% of cases being reported as 
being of an autosomal dominant inheritance, depending on the population 
studied (Bravo-Gil et al., 2017; Hartong et al., 2006). In excess of 150 
missense/nonsense RHO mutations are catalogued by the professional 
2017.1 release of the Human Gene Mutation Database (Stenson et al., 2014) 
(Reiff et al., 2016) (http://www.hgmd.cf.ac.uk/).  
 
Retinal pathologies resulting from mutations in the RHO gene can be inherited 
in either an autosomal dominant (ad) or autosomal recessive (ar) manner. 
Two disease states are associated with RHO mutations, RP and congenital 
stationary night blindness (CSNB). Whilst CSNB associated with a RHO 
mutation is inherited in an autosomal dominant manner (adCSNB), RP 
associated with a RHO mutation can be inherited in either an autosomal 
dominant (adRP) or autosomal recessive (arRP) form. Inherited variants in 
RHO are most often associated with adRP, while the recessive mode of 
inheritance is relatively uncommon. 
 
1.2.1 CSNB   
RHO associated adCSNB (MIM#610445; CSNBAD1; 
https://www.omim.org/entry/610445) is characterised by a lack of scotopic 
vision typified by an absence of detectable rod function by electroretinogram 
(ERG). Cone function typically appears normal. There are currently five RHO 
missense mutations associated with adCSNB: p.G90D (Rao et al., 1994; 
Sieving et al., 1995); p.T94I (al-Jandal et al., 1999); p.E113K (Reiff et al., 
2016); p.A292E (Dryja et al., 1993) and p.A295V (Zeitz et al., 2008) (Table 1). 
Whilst normally non-progressive in nature, peripheral pigmentary changes 
and retinal degeneration have been noted as a feature in older patients 
(Sieving et al., 1995), suggesting potential overlap with an adRP phenotype 
later in life. The E113K mutation is striking in that both CSNB and adRP are 
present in the same pedigree with phenotype seemingly not linked to age of 
patient (Reiff et al., 2016). With the exception of the E113K mutation, 
constitutive activation of rhodopsin due to these mutations is believed to be 
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the mechanism behind this form of adCSNB (Gross et al., 2003), see section 
2 and classification (Table 1). 
 
1.2.2 arRP  
Two missense RHO mutations, p.E150K (Azam et al., 2009; 
Kumaramanickavel et al., 1994; Saqib et al., 2015; Van Schil et al., 2016), 
and M253I (Collin et al., 2011); and two nonsense (premature stop codon) 
mutations,  p.W161ter (Kartasasmita et al., 2011) and p.E249ter (Rosenfeld et 
al., 1992), are associated with arRP  (Table 2). The observed homozygous 
recessive inheritance of loss-of-function RHO mutations and compound 
heterozygous RHO mutations causing arRP have yet to be identified. 
Interestingly, research on a knock-in (KI) mouse model of E150K suggests 
that this is actually a mild dominant mutation, which progresses more quickly 
in the homozygous state (Zhang et al., 2013). M253I was identified by 
homozygosity mapping and has not been studied in detail biochemically, but 
was also suggested to potentially be a mild mutation that is only pathogenic if 
present on both alleles (Collin et al., 2011). In contrast, it would appear that 
the p.W161ter and p.E249ter mutations might potentially cause a true null 
phenotype since the locations of the nucleotide substitutions, c.482G>A 
(TGG>TAG) and c.745G>T (GAG>TAG) in exon 2 and exon 4 respectively, 
suggest that nonsense mediated decay is likely to clear the premature stop 
codon containing mRNA transcript to an unknown degree (Hernan et al., 
2011; Roman-Sanchez et al., 2016). Rhodopsin is essential for rod cell 
function and rod cell survival, as homozygous rhodopsin (Rho) knock-out 
(KO) mice do not develop outer segments (OS) and show a progressive 
retinal degeneration (Humphries et al., 1997; Lem et al., 1999). By contrast, 
the heterozygous Rho KO mice do not display overt retinal degeneration, but 
show alterations in their photoresponses, OS morphology and have smaller 
disk membranes within their OS (Makino et al., 2012; Rakshit and Park, 
2015).  
 
1.2.3 adRP  
Currently more than 150 documented missense/nonsense RHO mutations are 
associated with an adRP phenotype (Table 1). Collectively, they are the most 
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common cause of adRP, accounting for 20-30% of all cases (Sullivan et al., 
2006). Whilst the P23H rod opsin mutation is arguably the most studied, it 
also likely represents a founder effect (Farrar et al., 1990), appearing to be 
confined to North America and seemingly accounting for ~10% of adRP cases 
in the USA in patients with a western European origin (Sullivan et al., 2006). 
The null alleles for arRP and lack of aggressive retinal degeneration in 
heterozygous Rho KO mouse models (Humphries et al., 1997; Lem et al., 
1999), suggest that haploinsufficiency is not the disease mechanism and that 
dominant mutations are typically gain-of-function or dominant-negative 
mutations. Several attempts have been made to classify RHO mutations on 
the basis of (a) their clinical manifestation e.g. (Cideciyan et al., 1998; Gal et 
al., 1997; Krebs et al., 2010), and (b) their biochemical and cellular behaviour 
e.g. (Kaushal and Khorana, 1994; Krebs et al., 2010; Mendes et al., 2005; 
Rakoczy et al., 2011; Sung et al., 1991). Cideciyan et al. (1998) developed a 
broad phenotype-genotype correlation of adRP RHO mutations consisting of 
two classes (Table 3). Clinical classifications typically have two major classes: 
class A that has early onset severe rod dysfunction; whilst class B is normally 
associated with a later onset, less severe phenotype with a slower 
progression (Table 3). The difference in rates of presentation are likely related 
to the underlying biochemical and cellular defects associated with the 
mutation, but other factors such as genetic modifiers and environment can 
also affect the presentation of a condition and/or lead to interfamilial variability 
(Iannaccone et al., 2006). Examples of known modifiers include different 
alleles of Rpe65 and light exposure, which are discussed in depth later. Here 
we have collated the available biochemical and cellular information to suggest 
potential classes for each dominant mutation (Table 1, Figure 2); however, 
given that RHO mutations cause RP through multiple potential mechanisms, 
this classification is not mutually exclusive, with some mutants potentially 
leading to consequences that are applicable to more than one class. 
 
1.3 Variation in the RHO gene, when is a variant a mutation?  
Given that RHO was the first gene in which RP causing mutations were 
identified (Dryja et al., 1990a; Dryja et al., 1990b), it received intensive 
screening in RP cohorts across the globe, and it was thus tempting to assume 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 13
that all variants in RHO identified in individuals with RP were likely 
pathogenic. Caution needs to be used, however, as some changes could be 
benign, especially where evidence of familial transmission is absent, such as 
in isolated patients, where there is no family history, or familial cases where 
other individuals in a pedigree have not been assessed and genotyped. The 
collection of data on human genetic variation has enabled researchers to 
investigate the frequency of nucleotide changes on an as yet unprecedented 
global scale (Lek et al., 2016). We used the Genome Aggregation 
Database (gnomAD; http://gnomad.broadinstitute.org/), which contains 
123,136 exome sequences and 15,496 whole-genome sequences from 
unrelated individuals and excludes patients with severe paediatric disease, to 
determine the allele frequencies for potential missense/nonsense RHO 
mutations and compared against the currently catalogued RHO mutations. 
Whilst presence in the gnomAD dataset does not exclude the possibility of 
and causing late onset disease, based on the prevalence of adRP associated 
with RHO mutations in the range between 1:20,000 and 1:150,000, we 
estimate that a fully penetrant adRP causing RHO variant cannot be more 
common than 1:20,000 (0.0005) and would more likely have a minor allele 
frequency of <1:80,000 (<0.0000125), otherwise they would be very common 
disease associated alleles. These analyses revealed that missense changes 
that had previously been reported as potential RHO ‘mutations’ such as G51A 
(Cideciyan et al., 1998; Macke et al., 1993), V104I (Macke et al., 1993), 
A333V (Eisenberger et al., 2013), and T340M (Clark et al., 2010; Stone, 
2003), are almost certainly benign single nucleotide polymorphisms (SNPs) 
with allele frequencies of between 1:1000 (G51A) and 1:10,000 (A333V). As a 
control, the T320N substitution that has been shown not to segregate with 
adRP (Mandal et al., 2005) exhibits a gnomAD frequency of 1:10,000. 
Therefore, we have excluded these five substitutions from our classifications. 
Whilst the presence of rare RHO variants in the general population (italicised 
variants in Table 1) questions their potential to cause fully penetrant 
aggressive adRP, they could still be associated with very mild late onset 
disease, arRP, or potentially act as disease modifiers. Nevertheless, these 
data reinforce the need for thorough genetics, such as segregation analyses, 
and in depth functional analyses to confirm pathogenicity. 
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2. Structural and biochemical basis of rhodopsin RP mutants 
Rhodopsin is a member of the class A family of GPCRs. Upon activation by 
light, rhodopsin couples with the G protein transducin to initiate the first step in 
vision. Rhodopsin is synthesised in the rod cell inner segments (IS) and 
transported to rod OS, where it is densely packed into stacks of membranous 
discs. Fully folded rhodopsin adopts a seven TM helical bundle configuration 
in these disc membranes (Figure 1). The N-terminus resides in the interior of 
the rod discs, while the C-terminus is in the cytoplasm of the OS. Rod opsin 
combines with its 11-cis-retinal ligand to form the dark-state rhodopsin 
pigment (visible λmax 500 nm).  
 
Biochemical examination of rhodopsin RP mutants have largely been 
undertaken by expressing them in cell culture model systems, such as COS-1 
and HEK293 cells. Such studies led to the initial identification of two major 
classes of mutant, class I and class II (Kaushal and Khorana, 1994; Sung et 
al., 1991). Upon recombinant expression, class I mutants formed rhodopsin 
pigment and reached the cell surface; whereas, class II mutants misfolded, 
formed rhodopsin pigment poorly, if at all, and were retained fully or partly 
within the endoplasmic reticulum (ER). Upon further examination using more 
relevant animal model systems (Table 4), class I mutants were found to be 
defective in trafficking to the OS, caused by a change to the C-terminal OS 
trafficking motif. This classification system was expanded to six groups based 
on additional criteria, such as thermal stability, transducin activation capability, 
constitutive activation and receptor endocytosis (Mendes et al., 2005). Here 
we have updated this classification and expanded to include a new class of 
rhodopsin mutation (Table 1).  
 
2.1 Structural and biochemical insight into rhodopsin RP mutants 
It is unclear why so many, often single point (missense), mutations in 
rhodopsin have such a large impact on folding of rhodopsin (class 2) and 
ultimately trigger such deleterious outcomes for rod cell structure and viability. 
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Wild-type (WT) rhodopsin is an exquisitely evolved photon-capturing device 
that has very low background noise. As such, the intricate nature of the 
interactions that keep the TM helical bundle intact, yet permit full receptor 
activation upon absorption of a single photon by the retinal chromophore 
moiety, imply a delicately balanced two state machine. As vision, and 
especially scotopic vision, is adapted to operation in low light, it might be that 
rhodopsin folding and the photoreceptor ER quality control system also 
evolved to allow only correctly folded receptors to reach the light sensing OS 
destination. In the case of adRP, the very high expression levels and 
biosynthesis rates of rhodopsin could lead to the production of considerable 
amounts of even mildly defective protein (25% of total rod cell protein). The 
requirement for this scale of enhanced folding or degradation might be too 
demanding for the rod cell to manage, ultimately leading to a breakdown of 
proteostasis. For these reasons, it is important to understand the differences 
in severity of RP (age of onset, extent and rate of degeneration) of different 
point mutations and correlate these with their biochemical and cellular 
consequences. It is also important to understand the precise molecular basis 
of the structural defects brought about by the different mutants. It is 
challenging to collect structural data for mutants that are, by definition, 
misfolded; however, such insight could be necessary for the development of 
therapeutic approaches that target the misfolded mutant receptors directly.  
 
2.2 The distribution of RP mutants in rhodopsin 
RP mutations are located throughout the rod opsin apoprotein (Figure 2). The 
molecular mechanisms of disease can be linked to different types of receptor 
malfunction.  
 
2.2.1 RP mutations located in the N-terminus of rhodopsin: the role of 
the N-terminal cap. 
In addition to P23H, other mutations located in the N-terminus of rhodopsin 
(residues M1 to Q35) include T4K, P23A/L, N15K, T17M, V20G and Q28H. 
The mutations in this N-terminal segment are sometimes associated with a 
relatively mild disease, with RP developing in later life and with slowly 
advancing symptoms (Table 3). Interestingly these mutations are often 
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associated with sector RP, whereby retinal damage is more prevalent at light-
exposed regions (sectors) of the retina (Jacobson et al., 1991; Kemp et al., 
1992; Krill et al., 1970; Ramon et al., 2014; Van Woerkom and Ferrucci, 
2005). The pattern of dystrophy in these sector mutants suggests a role of 
light exposure that is supported by biochemical data for non-N-terminal 
mutants e.g. N55K (Ramon et al., 2014). Therefore, these N-terminal mutants 
might not exert their deleterious effects entirely though protein misfolding in 
the ER, as indicated by early cell culture based experiments; however, light 
could also affect their biogenesis through altering the availability of 11-cis-
retinal, which could otherwise improve mutant receptor biogenesis (Tam and 
Moritz, 2007).  
  
The crystal structure of rhodopsin revealed how the N-terminal segment of 
rhodopsin folds into a cap-like structure that covers the second extracellular 
loop (EL2) ‘plug’ and is in contact with EL1 and EL3 (Figure 1) (Li et al., 
2004). Unlike most GPCRs that bind their ligands via an ‘open’ extracellular 
domain, rhodopsin and other visual receptors acquire the retinal ligand via 
distinct transient pores that open between the TM helices. This has allowed 
the extracellular (intradiscal) domain to evolve such that it contributes to the 
thermal stability of rhodopsin as well as the receptor activation process (Ahuja 
et al., 2009). This idea is supported by the observation that further stabilising 
the interaction between the N-terminal cap and the EL loops by engineering in 
an additional disulphide bond between residues N2(C) and D282(C) increases 
the thermal stability of the pigment and makes possible the isolation of the rod 
opsin apoprotein in detergent (Xie et al., 2003).    
 
Early experiments relied upon expression of rod opsin mutants in cell culture 
models (COS-1, HEK293) for preparation of mutant pigments (Kaushal and 
Khorana, 1994; Sung et al., 1991). In these experiments transfected cells 
were treated with the 11-cis-retinal ligand during purification, and prior to 
assessment of pigment formation capability. These results suggested that the 
N-terminal mutants were members of class 2 (misfolded, retained in the ER). 
Subsequent experiments using transfected cells treated with 11-cis or 9-cis 
retinal during expression revealed that N-terminal mutants could in fact form 
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pigments, if protein misfolding was rescued by the ligand functioning as a 
pharmacological chaperone (Krebs et al., 2010; Li et al., 1998a; Mendes and 
Cheetham, 2008; Noorwez et al., 2003; Saliba et al., 2002). We later showed 
that all the RP mutants in the N-terminus could be rescued by this procedure; 
however, all the pigments produced were defective and displayed much lower 
levels of thermal stability and had altered photobleaching and signal 
transduction behaviour (Opefi et al., 2013). Furthermore, a subset of these 
mutants could be repaired in the N2C/D282C rhodopsin background. That is, 
they could form pigment after completion of expression and by post-harvest 
treatment of the transfected cells with 11-cis-retinal. Additionally, these 
repaired mutant pigments had close to WT-like properties, but still showed 
decreased stability. Taken together, these results suggest that the N-terminal 
cap is needed to stabilise the rod opsin protein and the pigment, but it also 
plays a role in the rhodopsin photocycle and signalling through transducin.  
One explanation for the functional role of the N-terminal cap lies in its close 
proximity to the extracellular loops and extracellular ends of the TM helices. 
Solid state magic angle spinning (MAS) nuclear magnetic resonance (NMR) 
experiments have revealed changes in hydrogen bond interactions between 
TM6 and EL2 take place during light activation of rhodopsin (Kimata et al., 
2016). The N-terminal cap positioned over the EL2 could be required for the 
correct orientation of EL2 during the photoactivation process.  
 
In a separate study of rod opsin expression in transgenic C. elegans nervous 
system, the P23H protein was expressed at low levels, due to degradation 
and aggregation (Chen et al., 2014). The P23H could be partially rescued 9-
cis-retinal and form a purified pigment that had WT-like photocycle and signal 
transduction properties; however, the P23H mutant pigment formed slowly 
and was unstable (Chen et al., 2014). The capacity for pharmacological 
chaperone rescue with retinal suggests that in photoreceptors, in the 
presence of 11-cis-retinal, it might be stabilised and sufficiently folded to leave 
the ER and reach the rod OS. It is not clear from animal model studies, 
however, when 11-cis-retinal is inserted during rod opsin biogenesis. The 
possibility exists that if P23H pigment can reach the rod OS, even if in small 
amounts, it could disrupt the integrity of discs though its inherent instability 
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(see sections 3.4 and 5.1.1). This scenario is reminiscent of that described for 
class 4 mutants where receptor instability in the OS is the most likely 
explanation for cytotoxity (Mendes et al., 2005). Thus, we can consider class 
2 mutant receptor sub populations where folding is rescued by 
pharmacological chaperone 11-cis-retinal to gain a class 4 mutant phenotype.  
 
2.2.2 RP mutations in the transmembrane helices. 
Rhodopsin RP mutants have been described in each of the seven TM 
segments (Figure 2).  Many of these are point mutations that bring about the 
introduction of a charged amino acid into the TM segment, for example, L40R, 
L46R, G51R, P53R and T58R in TM helix 1 (Table 1). In most cases, it is 
likely that the presence of the basic (or acidic) residue is preventing insertion 
of the domain into the ER membrane and thus resulting in the type 2 
misfolding phenotype often associated with such mutations.  
 
More recent investigation into mutations located in TM1 focused on M39R and 
N55K associated with sector RP (Ramon et al., 2014). These mutants were 
expressed at lower levels in COS-1 cells and their pigment profiles indicated 
some degree of misfolding and decreased thermal stability. These pigments 
behaved differently in response to light, properties that could explain the 
sector RP pathology.  
 
RP mutations have also been found in the 11-cis-retinal attachment site K296 
(reviewed in (Park, 2014), as well as the K296 PSB counterion E113. 
Substitutions at K296 have been proposed to cause RP due to the close 
association of its constitutively phosphorylated form with arrestin, similar to 
class 3 mutants, and not due to activation of transducin (Park, 2014). The 
K296E mutant, however, also misfolds and is retained in the ER on 
heterologous expression (Saliba et al., 2002), suggesting a partial class 2 
phenotype. The recently identified E113K mutation has been shown to result 
in moderately progressive RP, as well as CSNB, in the same family (Reiff et 
al., 2016). The relatively mild phenotypes brought about by the E113K 
mutation are difficult to reconcile with previous cell culture and biochemical 
studies. When the E113K mutant was expressed using COS-1 cells it was 
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unable to form rhodopsin pigment and had abnormal mobility on SDS-PAGE, 
both hallmarks of a misfolded receptor of the class 2 mutants (Sakmar et al., 
1989). One possible explanation for this paradox is that if 11-cis-retinal is 
present during folding and functions as a pharmacological chaperone to 
rescue E113K folding (as described in section 2.2.1) then there could be a 
complete or near complete rescue. The E113K pigment that is formed might 
be constitutively active and lead to rod dysfunction similar to class 6 CSNB 
mutants.  
 
RP mutants in the TM helices could also give rise to the loss of side chains 
required for structure and function (e.g. H211P) or introduce bulky side chains 
into regions of tight helix packing. Crystal structures reveal the 7TM bundle of 
rhodopsin contains both tightly packed and more loosely packed helices 
(Sanchez-Reyes et al., 2017). Two separate interior packing clusters (1&2) 
were identified that mediate interactions between TM helices H1 and H2 or H3 
and H4 respectively. These packing clusters are conserved in GPCRs and are 
composed of amino acids with small side chains. The residue A164 is a 
component of packing cluster 2 and presumably its mutation to a more bulky 
valine (A164V) could disturb rhodopsin folding and stability by disrupting 
formation of this packing core leading to misfolding (Sanchez-Reyes et al., 
2017; Stojanovic et al., 2003).  
 
2.3 Structural studies of CSNB mutants 
Class 2 rhodopsin RP mutants have not been amenable to structural biology 
methods, such as X-ray crystallography, or NMR, because they are misfolded; 
however, insight into the molecular defects of rhodopsin mutations can be 
obtained by the study of mutant pigments where folding is not affected. For 
example, Singhal et al. (2016),  collected X-ray diffraction data from crystals 
of the rod opsin and light-activated forms of CSNB mutants, G90D and T94I. 
They found that a new salt bridge was formed between the aspartate residue 
in G90D and the K296 PSB retinal attachment site. This new salt bridge was 
proposed to be the reason for the increased basal activation in the dark of this 
mutant. By contrast, in T94I the introduced hydrophobic side chain prolonged 
the lifetime of the metarhodopsin II (meta II) state by establishing a contact 
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with K296 (Singhal et al., 2016). Therefore, both mutations alter the dark state 
by weakening the interaction between the PSB and its counterion E113, a 
concept that could also explain increased basal receptor activity for other 
CSNB mutants. It is important to understand why such mutations do not go on 
to cause the degenerative RP phenotype, or do so very slowly. One possibility 
is that signalling defects of this nature give rise to mild changes in rod cell 
physiology. Another possibility is that they are so mild that rod cell 
degeneration is very slow and is affected by other genetic and environmental 
modifiers.  
 
2.4 Dimerization deficiency in adRP mutants 
The ability for rhodopsin to form higher order oligomers in animal tissue was 
demonstrated by atomic force microscopy (Fotiadis et al., 2003). These 
observations have subsequently been supported by various biochemical and 
biophysical means (Fotiadis et al., 2003; Jastrzebska et al., 2015; Kota et al., 
2006). Furthermore, rows of dimers have been observed by cryo-electron 
tomography in dark adapted mouse photoreceptors (Gunkel et al., 2015). The 
role of these oligomeric rhodopsin structures in photoreceptor function 
remains controversial, but there is evidence that dimeric and multimeric 
interactions might begin during folding in the ER, as the biogenesis of mutant 
protein can affect the WT (Mendes and Cheetham, 2008; Rajan and Kopito, 
2005; Saliba et al., 2002). Recently, three previously reported RHO mutations 
that did not have a documented biochemical phenotype were examined for 
their ability to perform phospholipid scrambling and form dimers (Ploier et al., 
2016). These amino acid positions (F45, V209 and F220) are all located at the 
surface of TM1 or TM5 (Figure 2). The authors report that the variants (F45L, 
V209M and F220C) behaved as monomers, unlike the WT protein which 
formed dimers or multimers, suggesting that these mutations potentially lead 
to RP through an inability to dimerise (Ploier et al., 2016). We propose this 
defect could be classified as class 7 (Table 1). Variants at these three 
residues, however, are present in the general population in gnomAD at 
relatively high frequencies (F45L, 0.000022; V209M, 0.000012; F220C 
0.00002 and F220L 0.000049). Furthermore, genetic studies have shown that 
F45L, V209M and F220L did not segregate with disease in families (Davies et 
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al., 2012; Dryja et al., 2000; Lim et al., 2009), which suggests that they are not 
disease causing mutations. Therefore, at present, the significance of these 
residues and their effect of rhodopsin oligomerisation and lipid homeostasis in 
rhodopsin RP remains uncertain. 
 
3. Rhodopsin biogenesis, post-translational modifications and 
trafficking 
Rhodopsin is co-translationally translocated into the rod photoreceptor ER 
and trafficked to the OS, via the Golgi apparatus on membranous vesicle 
carriers (Figure 3). Early in its biogenesis, the N-terminus of rhodopsin 
becomes glycosylated at two asparagine residues: N2 and N15 (Figure 1 and 
2). For many proteins, glycosylation is necessary for the binding of ER 
chaperones (typically lectins) to assist protein folding and targeting misfolded 
species for ER-associated degradation (ERAD) (Helenius and Aebi, 2001). 
Although glycosylation is not required for WT rod opsin to fold sufficiently to 
exit the ER, glycosylation is essential for mutant rhodopsin ERAD (Saliba et 
al., 2002). Furthermore, a study of transgenic frogs found that non-
glycosylated rhodopsin (N2S/N15S) did not accumulate in the ER and 
trafficked to the OS, similar to T4K, T4N and T17M (Tam and Moritz, 2009). 
The expression of these mutants caused retinal degeneration in a light 
dependent manner, highlighting the importance of glycosylation at N15 for 
photoreceptor survival (Tam and Moritz, 2009). In addition, monoglycosylated 
rhodopsin is expressed at high levels and trafficked to the OS in the T4R 
rhodopsin dog retina, and also causes a light dependent degeneration (Zhu et 
al., 2004). Glycosylation is important for rhodopsin function, non-glycosylated 
mutants activate transducin poorly (Kaushal et al., 1994), and expression of a 
non-glycosylated mutant rod opsin in mouse rods led to very low levels of 
expression and OS that did not form (Murray et al., 2015a). 
 
In addition to glycosylation, rhodopsin is palmitoylated at the cysteine 
residues C322 and C323 (Ovchinnikov et al., 1988). This modification anchors 
the C-terminal tail to the disc membrane and loss of palmitoylation alters 
transducin activation (Wang et al., 2005). The formation of a disulphide bond 
between C110 (at the base of TM3) and C187 (in EL2) connects TM3 and 
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TM5 and is structurally essential for rhodopsin (Hwa et al., 1999; Karnik et al., 
1988; McKibbin et al., 2007). This modification helps maintain the structure of 
rhodopsin in its correct conformation throughout its synthesis and transport to 
the OS (Murray et al., 2009), and is important for the stability of the meta II 
structure and its coupling to transducin activation (Davidson et al., 1994). 
Misfolded rhodopsin due to mutations in the intradiscal domain are 
characterized by the formation of an incorrect disulphide bond between C185 
and C187, as opposed to the correct and highly conserved C110–C187 
disulphide bond (Athanasiou et al., 2014; Hwa et al., 1999; Liu et al., 1996).  
Rhodopsin has an OS targeting signal located within its cytoplasmic C-
terminal tail, the VXPX motif (Sung and Chuang, 2010; Tam et al., 2000). 
Deficiencies in this motif lead to mislocalisation of rhodopsin via mistrafficking 
and rod degeneration (Sung et al., 1994; Tam et al., 2000). 
 
3.1 Misfolding, ER retention and instability  
As described earlier, studies from cell culture models have shown that 
misfolded P23H rhodopsin is retained in the ER, suggesting the existence of 
an ER mechanism that does not permit further traffic of misfolded rhodopsin 
(Athanasiou et al., 2014; Athanasiou et al., 2012; Kaushal and Khorana, 1994; 
Kosmaoglou et al., 2009; Sung et al., 1991). Animal models of class 2 
mutants (Table 1 and Table 4), including P23H, also show ER retention and 
degradation of mutant rhodopsin accompanied by photoreceptor cell death; 
including Drosophila melanogaster (Wang and Montell, 2007), Xenopus laevis 
(Tam and Moritz, 2006, 2009), mice (Frederick et al., 2001; Olsson et al., 
1992), rats (Lee et al., 2003) and pigs (Ross et al., 2012).  More recently, 
P23H KI mice were generated with the same gene dosage as in adRP, in 
which at least 90% of the P23H was degraded and the remainder that exited 
the ER was found in structurally disorganised OS (Chiang et al., 2015; 
Sakami et al., 2011). 
 
Rhodopsin misfolding and ER retention has been shown to cause ER stress 
(Lin et al., 2007). Accumulation of unfolded proteins in the ER causes ER 
stress and cells respond to ER stress by activating the unfolded protein 
response (UPR), a signalling network initiated by the ER-anchored receptors 
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IRE1α, PERK and ATF6. The UPR aims to restore ER protein-folding 
homeostasis, but can turn into a lethal signal when the stress is too severe or 
prolonged, leading to cell death (Cao and Kaufman, 2012; Remondelli and 
Renna, 2017). 
 
Increases in BiP (binding immunoglobulin protein; HSPA5) expression are a 
hallmark of UPR activation. In Drosophila, the levels of heat shock cognate 
protein-3 (Hsc3), which is the homologue of the mammalian ER Hsp70, BiP, 
were increased in flies expressing the class 2 mutants G93D, and P37H (the 
P23H equivalent) in rhodopsin (Rh1) and in flies that lack NinaA, a peptidyl-
prolyl cis-trans isomerase chaperone that is required for Rh1 maturation 
(Griciuc et al., 2010b; Mendes et al., 2009). BiP mRNA levels were also highly 
elevated in HEK293 cells overexpressing P23H rod opsin, but not in cells 
expressing WT rod opsin (Lin et al., 2007). There was increased activation of 
the IRE1/XBP-1 UPR pathway, which could mediate the changes in BiP levels 
together with other branches of the UPR (Griciuc et al., 2010b; Lin et al., 
2007; Mendes et al., 2009). Additionally, in P23H rats, BiP mRNA levels were 
elevated after photoreceptor differentiation, but declined when degeneration 
progressed and this change was accompanied by the induction of pro-
apoptotic factors, such as CHOP, suggesting that the ER stress could not be 
overcome (Lin et al., 2007). Studies of the P23H KI mouse, however, showed 
lower levels of ER stress and efficient ERAD of the mutant protein (Chiang et 
al., 2015), suggesting that overexpression of rhodopsin might be a factor in 
the ER stress observed in these transgenic models.  
 
P23H rhodopsin is targeted for ERAD and proteasomal degradation by the 
ubiquitin proteasome system (UPS), but if degradation fails then rhodopsin 
can aggregate to form inclusions that are ubiquitylated and recruit Hsp70 
molecular chaperones (Illing et al., 2002; Saliba et al., 2002). Ubiquitylated 
inclusions, however, are rarely seen in photoreceptors in animal models in 
vivo, suggesting that aggregation is either infrequent or could lead to cell 
death before the formation of microscopically visible inclusions. Further 
evidence for a potential role of the proteasome in the pathogenesis of 
rhodopsin RP is that aggregation of P23H leads to a global impairment of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 24
proteasomal function, which could ultimately compromise the degradation of 
other misfolded protein substrates of the UPS (Bennett et al., 2005).  Indeed, 
an accumulation of a ubiquitin, Ub(G76V)–GFP, proteasomal substrate 
reporter was observed in P23H mouse photoreceptors, whereas other mouse 
models of retinal degeneration that do not involve protein misfolding did not 
show any proteasomal overload, suggesting proteasomal insufficiency might 
contribute to pathogenesis in the P23H transgenic mouse model (Lobanova et 
al., 2013).  
 
A potential type of dominant-negative effect of class 2 mutants at the level of 
the ER has also been observed, whereby the presence of the mutant protein 
interferes with the biogenesis and traffic of the WT protein. For example, co-
expression of WT and P23H rhodopsin in vitro resulted in the formation of 
inclusions containing the WT protein (Mendes and Cheetham, 2008; Saliba et 
al., 2002), and co-aggregation of the mutant and WT protein with enhanced 
proteasome-mediated degradation of the WT protein (Rajan and Kopito, 
2005). This property might not be shared by all rod opsin mutants, however, 
as the G188R mutant also aggregates, but has only small effects on the WT 
protein and they do not co-aggregate (Gragg et al., 2016). Therefore, 
mutations in rhodopsin that cause misfolding can lead to enhanced mutant, 
and WT, rhodopsin degradation; potential ER stress; aggregation and alter 
photoreceptor homeostasis (Figure 3).  
 
3.2 Post Golgi trafficking and OS targeting 
Point mutations at the C-terminus of rod opsin (e.g. V345M, P347S) and C-
terminal truncations (e.g. Q334ter) have been reported to affect OS transport 
(Sung et al., 1994; Tam et al., 2000), and are regarded as class 1 (Table 1, 
Figure 2). As discussed earlier, class 1 mutants have no obvious defects in 
heterologous cell culture expression models; however, expression in 
photoreceptors revealed their striking effect on post ER trafficking. The 
majority of class 1 mutants are clustered at the rhodopsin C-terminus (Sung et 
al., 1993; Sung et al., 1994; Tam et al., 2000). The integrity of the rhodopsin 
C-terminal OS targeting signal VXPX-COOH is important for photoreceptor 
survival, as mutations in this highly conserved motif cause severe forms of RP 
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(Table 3) (Berson et al., 2002). The expression of C-terminal truncations of 
bovine rhodopsin in HEK293 cells showed that the proximal region (311-316) 
of the carboxyl terminus is critical for the proper folding and stability of the 
rhodopsin molecule, but that amino acids 316 to 348 were not necessary for 
the activation of transducin (Weiss et al., 1994). Different studies in transgenic 
mice, rats, pigs and frogs carrying mutations in this C-terminal sorting signal 
resulted in mistrafficking, leading to the accumulation of rhodopsin at the IS, 
plasma membrane and synapses (Concepcion and Chen, 2010; Green et al., 
2000; Li et al., 1998b; Sung et al., 1994; Tam et al., 2000). In frogs, rhodopsin 
without the VXPX motif cannot bind to ADP Ribosylation Factor 4 (Arf4), a 
small G protein important for packaging the rhodopsin transport carrier (RTC) 
vesicles in the IS (Deretic and Wang, 2012). Consequently, RTC packaging 
and trafficking becomes compromised, leading to accumulation or 
mistrafficking to IS structures, including endosomes, lysosomes, and the Golgi 
apparatus. Arf4 recruits other trafficking components, such as ASAP1 
(ArfGAP with SH3 Domain Ankyrin Repeat and PH Domain 1), Rab11, 
Rabin8, and Rab8, to the RTCs. Defects in the coordination of these 
trafficking components can contribute to rhodopsin mislocalisation (Wang et 
al., 2012). The role of Arf4 in rhodopsin transport has been challenged, 
however, by a recent study of Arf4 deletion in mouse photoreceptors, which 
showed no protein mislocalisation or retinal degeneration (Pearring et al., 
2017). Instead, it was suggested that the IFT20 subunit of the intraflagellar 
transport (IFT) particle was important for rhodopsin sorting, or transport from 
the Golgi to the OS in mammals, as inducible knockout of IFT20 in mouse 
photoreceptors caused rhodopsin accumulation in the Golgi membranes 
(Keady et al., 2011). 
 
The presence of a large quantity of mutant rhodopsin is likely to significantly 
alter the physical properties, the composition, and the function of the affected 
membranes in different photoreceptor compartments (Figure 3) (Deretic, 
2006). It has been suggested that accumulation of truncated rhodopsin in 
various ectopic membrane locations can be toxic and contribute to 
photoreceptor cell death by disrupting synaptic transmission, overloading the 
degradation machinery or decreasing the availability of functional proteins 
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important for the phototransduction process in the regions where the aberrant 
rhodopsin is concentrated (Alfinito and Townes-Anderson, 2002). For 
example, mislocalised Q344ter can ectopically initiate signalling in the IS and 
outer nuclear compartments (Concepcion and Chen, 2010), and prolonged 
photoreceptor responses due to loss of phosphorylation sites results in an 
S334ter mutant results in abnormal rhodopsin deactivation and might lead to 
OS shortening and photoreceptor cell death (Lee and Flannery, 2007). In 
contrast, expression of a K296R substitution, which blocks the ability of rod 
opsin to bind chromophore and activate transducin, in combination with 
Q344ter in Xenopus laevis did not alter the rate of degeneration, suggesting 
that the effects of mislocalised rhodopsin are not mediated by the activated 
form of rhodopsin (Tam et al., 2006). Therefore, the mechanisms of 
mislocalised rhodopsin mediated cell death are currently unclear.  
 
3.3 Disrupted vesicular traffic and endocytosis 
In addition to the effect of C-terminal mutations on rhodopsin traffic, other 
mutations can affect vesicle traffic. In particular, inherited amino acid 
substitutions at R135 in rhodopsin cause a severe and fast progressing form 
of RP (Table 1 and 3) (Iannaccone et al., 2006). This residue is conserved in 
all rhodopsin (class A) family GPCRs, and it has been suggested to play an 
important role in the regulation of G protein signalling. Mutations at this 
residue form their own class (class 3), as they have distinct biochemical and 
cellular defects compared to the other characterised rhodopsin mutants 
(Aguila et al., 2014; Mendes et al., 2005; Chuang et al., 2004). In particular, 
the R135L mutant appears to fold normally and exit the ER, but similar to 
some of the constitutively active mutants, it is constitutively phosphorylated 
and binds with a high affinity to visual arrestin in the absence of chromophore 
(Aguila et al., 2014; Chuang et al., 2004).  The R135L rhodopsin recruits 
cytosolic arrestin to the plasma membrane, and the rhodopsin-arrestin 
complex is internalized into the endocytic pathway, leading to an 
accumulation in the photoreceptor IS and preventing traffic to the OS (Figure 
3). Rhodopsin class 3 mutants might cause disease by disrupting the dynamic 
interplay between different endocytic compartments and rendering them 
dysfunctional. The resulting imbalances, for example in iron and nutrient 
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levels, might cause subsequent photoreceptor degeneration (Song and 
Dunaief, 2013); however, as yet there are no good animal models of class 3 
mutants, so the precise mechanisms remain to be elucidated. 
 
3.4 Altered post-translational modifications and reduced stability 
The class 4 group of mutations (Table 1) do not appear to directly affect 
rhodopsin folding at physiological expression levels, but instead affect 
rhodopsin stability and posttranslational modifications. A naturally occurring 
dog model of RP caused by a T4R substitution (Table 4) disrupts 
glycosylation at N2 (Kijas et al., 2002). These dogs are extremely sensitive to 
light-mediated retinal damage and exhibit high levels of the AP-1 apoptosis 
marker after acute exposure to light (Cideciyan et al., 2005; Zhu et al., 2004). 
No evidence of UPR activation was observed in the canine T4R rhodopsin 
model, but Hsp70 transcription levels were upregulated in the light-exposed 
retinas, suggesting induction of the heat shock response (HSR); however, no 
differences in the protein levels of Hsp70 (or Hsp90) were observed (Marsili et 
al., 2015). This could reflect a relatively small increase in protein level, or that 
the stress led to cell death before the mRNA could be translated into protein.  
 
Similarly, the T17M rhodopsin mutation abolishes glycosylation at the N15 site 
of rhodopsin and mouse models of T17M are also very susceptible to light 
damage (White et al., 2007). Studies in transgenic frogs of T4K and T17M 
mutations supported light activation as the cause of pathology, as abolishing 
photoexposure significantly reduced rod cell death (Tam et al., 2014). This 
highlights how environmental light exposure could influence disease 
progression in adRP patients. Overexpression models of T17M, however, 
share some of the characteristics of class 2 mutants with ER retention and 
induction of the UPR (Jiang et al., 2014b; Kunte et al., 2012). Interestingly, 
studies of P23H KI mice, P23H-GFP KI mice and in Xenopus have 
demonstrated that, similar to class 4 mutants, some P23H rhodopsin can 
escape the ER and be transported to the OS (Price et al., 2011; Sakami et al., 
2011; Tam and Moritz, 2007; Tam et al., 2014). In the OS the mutant 
rhodopsin can undergo time dependent aggregation leading to vesiculo-
tubular structures and destabilisation of rod photoreceptor disk membranes 
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(Haeri and Knox, 2012; Haeri et al., 2013) that are exacerbated by light 
(Bogea et al., 2015) (Figure 3). Therefore, inhibition of rhodopsin 
glycosylation by T4R and T17M mutations, or a failure of the ER quality 
control machinery to retain class 2 mutant proteins, results in protein reaching 
the OS that is unstable and affected by exposure to light, leading to 
photoreceptor cell death. Mutations at these residues cause retinal 
degeneration predominantly in the lower hemisphere, consistent with light-
induced damage from overhead sources (Jacobson et al., 1991; Kemp et al., 
1992; White et al., 2007). Some sector RP mutants, such as N55K, could also 
fall into this class of mutations (Table 1), as they display apparently, normal 
folding but have inherent structural instability (Ramon et al., 2014). The effect 
of the oligomerisation mutants on OS stability is not currently clear, but it is 
possible that they could disrupt the higher order organisation of rhodopsin 
within discs and have similar effects on photoreceptor survival.  
 
3.5 Altered transducin activation 
The M44T and V137M RP associated variants share spectral and structural 
features with WT rhodopsin (Table 1), but have significantly increased 
transducin initial activation rates (Andrés et al., 2003), such that they are class 
5 (Figure 2). It was suggested that these mutants have altered stoichiometric 
balance of the different proteins involved in the phototransduction biochemical 
reactions. These mutants, however, have no activity in the dark or absence of 
chromophore, suggesting that constitutive activity is not the basis of their 
pathogenesis (Park, 2014). 
 
3.6 Constitutive activation 
Class 6 mutants (Table 1, Figure 2) show constitutive activation of rod opsin 
in the absence of chromophore and in the dark. The constitutive activation of 
the phototransduction cascade has been suggested as a potential mechanism 
of cell death in RP. Intriguingly, the majority of rhodopsin mutations clustered 
around the chromophore binding pocket lead to constitutive activation, and 
are associated with rod dysfunction through CSNB, not rod cell death with 
secondary cone cell death in RP (Gross et al., 2003). For example, the G90D 
mutation has been described as causing CSNB (Sieving et al., 1995). Studies 
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in vitro showed that the G90D mutant activates the visual cascade in the dark 
or without chromophore (Rao et al., 1994). Constitutive activity was also 
observed in the G90D transgenic mice and frogs, acting as if in the presence 
of continuous background light (Dizhoor et al., 2008). Interestingly, another 
mutation at the same G90 position, G90V, was reported to be associated with 
RP not CSNB (Toledo et al., 2011). Furthermore, K296E mutation that causes 
RP can also activate transducin constitutively. This mutant was proposed to 
cause RP due to its ability to sequester cellular components needed for the 
shut-off process, such as arrestin, similar to class 3 mutants, rather than its 
constitutive activity (Chen et al., 2006); however, other reports suggest that 
K296E is also prone to misfolding and be retained in the ER, similar to class 2 
mutants (Saliba et al., 2002; Tam and Moritz, 2006). G90V also affects the 
thermal stability of the protein (Toledo et al., 2011), suggesting some overlap 
with class 4 mutants. 
 
Two other CSNB mutations leading to constitutive transducin activation are 
A292E and T94I (al-Jandal et al., 1999; Dryja et al., 1993). A292E and T94I 
constitutively activate transducin in vitro in the absence of chromophore, by 
disrupting the interaction between E113 and K296 that contributes to 
stabilisation of the protein in the inactive state. The T94I mutant has a long-
lived meta II intermediate in comparison to the WT and the other CSNB 
mutants (Gross et al., 2003; Ramon et al., 2003). Aberrant activation of 
rhodopsin leads to the inability of the rod cell to respond to dim light, which 
manifests as night blindness; however, it appears that rod dysfunction alone is 
not sufficient to lead to rod cell death and RP.  
 
4. Photoreceptor cell death  
Rhodopsin RP mutations lead to photoreceptor cell death by a two-stage 
process. Firstly, the rod photoreceptors degenerate and this leads to the 
second stage, which is death of cone photoreceptors. Despite the availability 
of various animal models, the mechanisms underlying the eventual loss of 
cone photoreceptors and the loss of daylight vision remain largely unknown.  
 
Classical apoptosis depends on activity of caspase-type proteases, with 
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caspase-3 as the prototypic mediator and executioner of apoptotic cell death 
(Porter and Janicke, 1999). Caspase-independent apoptosis includes calpain 
and PARP (poly(ADP-ribose) polymerase) activity. Calpains are a group of 
calcium-activated proteases that have been implicated in neuronal 
degeneration in a number of different neuronal tissues, including the retina. 
Calpain activity may result in an increased production of reactive oxygen 
species (ROS) and accumulation of oxidative DNA damage by abolishing AIF 
(apoptosis-inducing factor) oxidoreductase activity and OGG1 (8-Oxoguanine 
glycosylase)-dependent DNA repair activity. In conjunction with ROS 
production, calpain activity has been suggested as a cause of lysosomal 
membrane disruption with the resultant leakage and activation of various 
hydrolytic enzymes, in particular cathepsins (Wang et al., 2009). 
 
Early studies on RP proposed apoptosis as the final common pathway in 
retinal degeneration (Chang et al., 1993). While a number of publications 
suggested an involvement of apoptosis, a more recent study of P23H and 
S334ter rats identified the presence of non-apoptotic markers of cell death in 
these two rhodopsin models (Kaur et al., 2011). Both P23H and S334ter rats 
showed activation of calpain and PARP, associated with calpastatin down-
regulation, increased oxidative DNA damage and accumulation of 
PARpolymers. Interestingly, activation of caspases-3 and -9 and cytochrome 
c leakage were observed only in the S334ter mutant, which also showed 
increased expression of PARP-1. These results suggested that downstream 
cell death mechanisms triggered by different genetic mutations, in different 
species, share a number of key components (Kaur et al., 2011). The 
involvement of calpains in retinal degeneration was also demonstrated after 
light damage in the T4R dog (Marsili et al., 2015).   
 
Disruption of ER function affects other cellular pathways including oxidative 
stress (Bhandary et al., 2012), cytosolic Ca2+-release (Figure 3) (Kaufman 
and Malhotra, 2014) and inflammation (Garg et al., 2012). For instance, 
studies on the rhodopsin mutants T17M and E349X have shown significant 
up-regulation of pro-inflammatory markers associated with an ER-stress 
response (Rana et al., 2014). 
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Recent studies have shown that cellular necrosis can also contribute to cone 
and rod degeneration in animal models of retina degeneration (Murakami et 
al., 2012; Trichonas et al., 2010). Necrosis, which was traditionally thought to 
be an uncontrolled process of cell death, is now known to also have a 
regulated component (Holler et al., 2000; Matsumura et al., 2000). The 
receptor-interacting protein kinases (RIP), RIP1 and RIP3, have been 
identified as critical mediators of programmed necrosis (Vandenabeele et al., 
2010). It has been suggested that the ER-stress response in the P23H-1 rat 
results in necroptosis in rod photoreceptors due to up-regulation of RIP1/RIP3 
complexes and increased mitochondrial fission factor DRP1 and mitochondrial 
protein phosphatase PGAM5 activity, that subsequently leads to an influx of 
calcium into mitochondria to trigger necroptosis (Viringipurampeer et al., 
2016). Rod photoreceptors undergoing necroptotic cell death could release 
their cellular contents acting as damage-associated molecular patterns 
(DAMPS), which leads to inflammasome activation in cones (Murakami et al., 
2015). Studies of the P23H-1 rat model suggest that the secondary cone cell 
death occurs via pro-inflammatory mechanisms and it was proposed that 
activation of the NLRP3-dependent inflammasome could drive cone 
photoreceptor cell death in rhodopsin RP (Viringipurampeer et al., 2016).  
 
In contrast, a study using four different mouse models of RP, including 
rhodopsin RP, suggested that cone cell death could also be the result of 
prolonged starvation, caused by activation of autophagy. Downregulation of 
the insulin/mTOR pathway, a key pathway that regulates cellular metabolism, 
was observed during the period of cone degeneration leading to the 
suggestion that glucose uptake and/or the intracellular levels of glucose may 
be compromised in cones in RP (Punzo et al., 2009). A recent study in mice 
suggested that loss of mTOR does not affect cone survival; however, 
deregulation of this pathway in diabetes decreased cone function (Ma et al., 
2015). Therefore, although the mechanisms of rod and cone cell death in 
rhodopsin RP remain to be fully defined and might vary for different mutations, 
the opportunity exists to intervene and preserve vision.  
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5. Therapeutic approaches to rhodopsin RP 
Photoreceptors require a stringent regulation of proteostasis for their function 
and viability. Therefore, their vulnerability to the toxic gain-of-function effects 
of mutant rhodopsin could reflect their long-term inability to maintain 
proteostasis in the presence of this additional stress. Proteostasis 
mechanisms have been a therapeutic target in several studies which aimed to 
correct misfolding, reduce rhodopsin aggregation, enhance the degradation of 
mutant rhodopsin, stimulate autophagy or enhance cell survival. Manipulation 
of these mechanisms can be achieved by either the use of drugs that restore 
proteostasis (i.e. pharmacological chaperones, kosmotropes, molecular 
chaperone- or autophagy-inducers) or by targeting key components in the 
photoreceptor proteostasis network (e.g. ER quality control, ERAD, UPR) or 
with cell death inhibitors and neurotrophic factors. Some of these strategies 
have been shown to prolong cell survival both in cell culture systems and in 
animal models of disease, indicating the potential importance of proteostasis 
for controlling rhodopsin RP. 
 
5.1 Approaches for restoring proteostasis 
 
5.1.1 Pharmacological chaperones and methods to improve folding. 
Pharmacological chaperones are substrate-specific, small molecules that are 
designed to target directly the protein structure and shift the protein folding 
equilibrium towards the native state. For example, retinoids (9-cis and 11-cis-
retinal) or non-isomerisable retinoid analogues (11-cis-7-ring retinal) have 
been shown to promote P23H rod opsin trafficking and folding in vitro (Krebs 
et al., 2010; Mendes and Cheetham, 2008; Noorwez et al., 2003; Noorwez et 
al., 2009; Opefi et al., 2013; Saliba et al., 2002), and protect cells from the 
toxic effects of mutant rod opsin (Mendes and Cheetham, 2008). While 
improving rod opsin folding in vitro opened the possibility for pharmacological 
rescue of P23H, and other class 2 rod opsin mutants, to treat this form of 
retinal degeneration, promoting P23H folding and stability with such 
compounds in vivo has been proved to be challenging (see section 5.3). 
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More recently, the AMPK activator metformin was used as an alternative 
approach to promote rhodopsin folding, via regulation of protein translation 
(Athanasiou et al., 2017a). Metformin improved P23H folding and traffic and 
reduced cell death in cell models, but did not appear to act as a 
pharmacological chaperone, as it did not bind directly to rhodopsin. Instead it 
improved folding through altering the cellular milieu and the rate of translation. 
In contrast to the effect in cell culture, metformin accelerated retinal 
degeneration in the P23H-1 rat model and P23H KI mouse, as the metformin-
rescued P23H that trafficked to the OS in larger amounts was still intrinsically 
unstable and destabilised the OS (Athanasiou et al., 2017a). This would agree 
with other studies of P23H stability (Chen et al., 2014; Opefi et al., 2013) and 
the potential of mutant P23H that escapes ER quality control to disrupt and 
destabilise OS structure (Bogea et al., 2015; Haeri and Knox, 2012; Haeri et 
al., 2013; Sakami et al., 2011). Therefore, these studies suggest that 
correction of mutant rhodopsin folding, without improving rhodopsin stability, 
could further compromise the OS and exacerbate rod cell death. Thereby, 
emphasising the need to focus on other treatment strategies such as 
promoting mutant rhodopsin degradation, reducing rhodopsin aggregation, 
and/or promote mutant opsin stability by other means, such as the use of 
allosteric ligands.  
 
5.1.2 Kosmotropes 
Kosmotropes, also known as chemical chaperones, are small, low molecular 
weight compounds that can improve the stability of proteins in their native 
conformation and reduce aggregation. Kosmotropes bind to proteins non-
specifically and, therefore, have a potential to be used to a variety of protein 
misfolding diseases. The kosmotrope sodium 4-phenylbutyrate (4-PBA) is 
clinically approved for use in children with urea cycle disorders and for the 
treatment of sickle cell disease, thalassemia, and cystic fibrosis (Perlmutter, 
2002). In vitro studies have shown that 4-PBA could decrease P23H rod opsin 
aggregation (Mendes and Cheetham, 2008) and reduce UPR signalling and 
ER stress associated with the T17M rod opsin mutation by promoting its 
degradation (Jiang et al., 2014a). Additionally, 4-PBA prevented the induction 
of the UPR and reduced apoptosis in RP17 associated with carbonic 
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anhydrase mutations (Bonapace et al., 2004). In glaucoma, 4-PBA has been 
shown to decrease misfolded myocillin aggregation and apoptosis both in 
cells, and in mice (Yam et al., 2007; Zode et al., 2011). Importantly, 
administration of 4-PBA in the Rpe65 (R91W) mouse model of Leber 
congenital amarausis (LCA), which has mislocalisation and misfolding of cone 
opsin due a deficiency of 11-cis-retinal, led to improvement of cone opsin 
traffic accompanied by improvement in cone survival and vision (Li et al., 
2016). Despite these data and the protection observed in the P23H cell model 
(Mendes and Cheetham, 2008), we did not observe any improvement of 
photoreceptor function, or amelioration of degeneration, in the P23H-1 rat 
model (Table 4) after systemic treatment with 4-PBA for up to 7 weeks as 
assessed by ERG and retinal histology (Figure 4). This suggests that, in 
contrast to misfolded cone opsins, 4-PBA does not act as a chemical 
chaperone for misfolded rhodopsin in vivo and therefore it does not protect 
against photoreceptor degeneration in the P23H rat model of RP. By contrast, 
the kosmotrope curcumin was reported to improve photoreceptor function and 
morphology in P23H-1 rats by reducing P23H aggregation and ER stress and 
by enhancing rhodopsin localisation to the rod OS (Vasireddy et al., 2011). 
 
The chemical chaperone tauroursodeoxycholic acid (TUDCA) is a component 
of bear bile that inhibits apoptosis by preventing Bax from being transported to 
the mitochondria to initiate caspase release (Boatright et al., 2009). TUDCA 
has excited a lot of interest in eye research, as it has been shown to be 
beneficial in several retinal degeneration models. For instance, TUDCA 
preserved photoreceptor structure and function in an LCA (Lrat-/-) model (Fu 
and Zhang, 2014; Zhang et al., 2012), in the Rd1 (Lawson et al., 2016) and 
Rd10 mouse models of phosphodiesterase (PDE) RP (Drack et al., 2012; 
Oveson et al., 2011; Phillips et al., 2008) and prevented obesity in Bardet-
Biedl syndrome Type I mice (Drack et al., 2012). Importantly, TUDCA slowed 
retinal degeneration in the lower copy number and slower degenerating 
P23H-3 rat (Table 4) model of rhodopsin RP, preserving photoreception 
function and survival and improving their connectivity with horizontal and 
bipolar cells (Fernandez-Sanchez et al., 2011). TUDCA also preserved 
photoreceptor function and survival in the fast degenerative P23H-1 rat 
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model, since we observed significant increase in the a-wave, which 
corresponds to photoreceptor function, (Figure 5A) and outer nuclear layer 
(ONL) thickness (Figure 5B) in treated rats.  We did not observe the same 
protection, however, after a longer treatment with TUDCA in the P23H KI 
mouse model (Figure 5C-D). TUDCA’s main suggested mechanism of action 
is to reduce ER stress. While the UPR is induced in the P23H-1 rats (Lin et 
al., 2007; Parfitt et al., 2014), the P23H KI model shows only activation of the 
IRE1 branch leading to a robust degradation of P23H and no PERK activation 
(Chiang et al., 2015), which might explain why TUDCA did not have a similar 
effect in these two models. Despite the effectiveness of TUDCA to protect 
photoreceptors in a range of animal models, its use in man could be limited by 
the required efficacious dose (500 mg/kg) and its unpleasant taste. In a recent 
study, however, Fernandez-Sanchez et al. (2017) demonstrated that 
biodegradable microspheres containing traces of TUDCA could be 
administered intravitreally in P23H-3 rats and prevent retinal degeneration 
and vision loss. This method provided a safe and long-term intraocular 
delivery of TUDCA with a neuroprotective effect, hence opening up the 
possibility for future clinical trials with this drug, if the effect can be validated in 
other models with the right gene dosage.   
 
5.1.3 Molecular chaperone inducers and autophagy inducers  
An alternative way to restore proteostasis is through manipulation of the 
cellular milieu and, in particular, the adaptive machinery that maintains 
proteostasis: the molecular chaperone machinery; the HSR; the UPR; and 
autophagy. The induction of the HSR is inhibited by the binding of molecular 
chaperones to heat shock factor (HSF1), which keep it as a monomer. 
Following cell stress the chaperones are recruited to misfolded proteins and 
allow HSF1 to trimerise and signalling cascades complete the activation. 
Therefore, inhibition of molecular chaperones can induce the HSR by 
releasing HSF1 and enhancing cell stress, which stimulates the production of 
molecular chaperones. The Hsp90 inhibitors and HSR inducers 
geldanamycin, radicicol and 17-AAG reduced P23H aggregation and cell 
death in cell culture (Mendes and Cheetham, 2008). Furthermore, 17-AAG, in 
combination with temporary permeabilisation of the blood retinal barrier, 
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supressed retinal degeneration in an IMPDH1 mouse model (Tam et al., 
2010b). Moreover, a single low systemic dose of the blood retinal barrier 
permeable Hsp90 inhibitor, HSP990, stimulated the HSR in the retina, 
reduced P23H aggregation, improved ERG responses and protected against 
photoreceptor cell death in P23H-1 rats (Aguila et al., 2014). Hsp90 inhibition 
also protected against the adverse effects of R135L rod opsin on endocytosis 
in cells and in the retina. This was not mediated through the HSR, however, 
but was a direct consequence of inhibiting Hsp90 function. Hsp90 functions as 
an essential chaperone in the maturation of many proteins, in particular 
protein kinases that can function as oncogenes, making it an attractive target 
for cancer therapy. Hsp90 inhibition reduced rhodopsin R135L 
hyperphosphorylation and arrestin binding, because of post-translation loss of 
rhodopsin kinase (GRK1), which mediates mutant rhodopsin 
hyperphosphorylation and is an Hsp90 client kinase (Aguila et al., 2014). 
Sustained Hsp90 inhibition also affected the biogenesis of PDE, and affected 
ERG responses (Aguila et al., 2014). A range of Hsp90 inhibitors have been 
developed and used in clinical trials for cancer (Butler et al., 2015); therefore, 
targeting Hsp90 in oncology, or as a way to induce the HSR, could also affect 
normal vision and other means of inducing the HSR might be more 
appropriate. Interestingly, the heat shock protein co-inducer arimoclomol 
might be a good alternative as it stimulated both the HSR and the UPR 
pathways in P23H retina, reduced P23H aggregation and ameliorated 
photoreceptor degeneration in both P23H-1 and P23H-3 rat models (Parfitt et 
al., 2014). 
 
Another major cellular pathway for dealing with misfolded proteins and their 
removal is autophagy. Treatment with the autophagy-inducer rapamycin in 
cells expressing P23H reduced P23H aggregation (Mendes and Cheetham, 
2008), and enhanced P23H degradation and colocalisation with autophagic 
markers (Kaushal, 2006). Systemic administration of rapamycin to P23H-3 
rats slowed rod cell degeneration, but did not affect cones suggesting that 
inhibition of the mTOR pathway, and activation of autophagy is particularly 
protective for rod cells (Sizova et al., 2014).  
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5.1.4 Targeting individual proteins to restore proteostasis 
Targeting key components of the photoreceptor proteostasis network could 
also enable photoreceptors to deal with misfolded rhodopsin. For instance, 
the chaperone network between ER degradation-enhancing α-mannosidase-
like 1 (EDEM1), ERdj5 (DNAJC10) and BiP has been shown to interact with 
mutant rhodopsin and individual overexpression of these proteins reduced 
P23H aggregation and promoted rhodopsin degradation in cell models 
(Athanasiou et al., 2014; Athanasiou et al., 2012; Kosmaoglou et al., 2009). 
BiP overexpression also reduced ER stress and photoreceptor cell death in 
P23H rats (Gorbatyuk et al., 2010). Moreover, studies in Drosophila have 
shown that valosin containing protein, VCP/p97, can also enhance mutant 
Rh1 degradation (Griciuc et al., 2010a); however, genetic inactivation of VCP 
protected flies from retinal degeneration, suggesting that excessive rhodopsin 
dislocation from the ER and/or degradation can be detrimental to 
photoreceptors (Griciuc et al., 2010b). 
 
Several studies have reported the induction of UPR in retinal degeneration; 
however, it is still uncertain whether activation of UPR is an adaptive, 
protective mechanism, part of the disease pathology, or a secondary effect 
due to the death of photoreceptors. The data from different rhodopsin models 
support each of these potential outcomes, in particular, for the PERK effectors 
ATF4 and CHOP, which is proposed to be a pro-apoptotic factor. For 
instance, reduction of CHOP levels in the T17M mouse model of RP led to 
reduction of photoreceptor function and survival. This was accompanied by a 
reduction of rhodopsin mRNA levels and down-regulation of important 
photoreceptor transcriptional factors, such as neural retinal leucine zipper 
(Nrl) and cone-rod homeobox (Crx), suggesting that CHOP plays a protective 
role in T17M-related RP (Nashine et al., 2013). By contrast, reduction of 
CHOP levels in the VPP (P23H) transgenic mouse model did not affect 
photoreceptor function. In later stages of disease, however, CHOP depleted 
mice showed less degeneration in the central retina suggesting that CHOP 
reduction might influence late stage responses of surrounding cells and/or 
other ongoing cellular responses in the retina to dying photoreceptors and 
thereby prolong cell survival in older animals (Adekeye et al., 2014). 
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Moreover, depletion of CHOP in the P23H KI mouse model did not affect 
photoreceptor numbers, indicating that photoreceptor cell death in this model 
occurs independently of CHOP (Chiang et al., 2015). Interestingly, there was 
still an induction of IRE1 in the P23H KI retina in this study after many of the 
photoreceptors had died, suggesting that the cell death might be independent 
of the UPR and could arise from other retinal cells (Chiang et al., 2015).  
 
On the other hand, reduction of ATF4 protected T17M rhodopsin mice from 
retinal degeneration by reducing apoptosis and promoting autophagy, 
whereas overexpression of ATF4 in the retina of T17M mice via AAV delivery 
accelerated retinal degeneration (Bhootada et al., 2016). In addition, 
intravitreal administration of KIRA6, which was designed to inhibit regulated 
IRE1-dependent mRNA decay (RIDD), a process that cleaves RNA to either 
preserve ER homeostasis or induce cell death, appeared to preserve 
photoreceptor numbers in P23H-1 rats (Ghosh et al., 2014), suggesting that 
activation of the UPR is part of the pathology. In contrast, studies of the P23H 
KI mouse revealed no c-Jun N-terminal kinase activation or RIDD, suggesting 
an adaptive response of the UPR and not chronic cell death activation 
(Chiang et al., 2015; Hiramatsu et al., 2015). 
 
Furthermore, arimoclomol treatment, which potentiated all the three UPR 
branches in P23H rats correlated with reduced retinal degeneration, indicating 
that UPR activation per se is not detrimental (Parfitt et al., 2014). More 
recently, inhibition of the PERK branch of the UPR with the specific inhibitor 
GSK2606414 accelerated retinal degeneration and enhanced rhodopsin 
aggregation in P23H-1 rats, whereas inhibition of eIF2a phosphatase with 
salubrinal improved photoreceptor survival (Athanasiou et al 2017b), further 
suggesting that activation of PERK in this adRP model is part of a protective 
mechanism. In addition, enhanced ERAD and the induction of ER stress in 
Drosophila protects against Rh1 mutants (Kang and Ryoo, 2009; Mendes et 
al., 2009), suggesting a protective role for ERAD and the UPR. Considering 
all the above, further studies need to be conducted in different models of 
rhodopsin RP with the right gene dosage to elucidate the exact role of each of 
the UPR branches in photoreceptor degeneration.  
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5.2 Histone deacetylase inhibitors  
Valpropic acid (VPA) has been used clinically as an anticonvulsant (epilepsy), 
mood stabiliser (bipolar disorder) and for migraine prevention. VPA is a 
pleiotropic drug, but is thought to act mainly as a histone deacetylase (HDAC) 
inhibitor. HDAC inhibitors can alter gene expression non-specifically and can 
have protective or negative effect in different cell and animal models of 
neurodegeneration (Chuang et al., 2009). In animal models, VPA provided 
neuroprotection and regeneration of retinal ganglion cells after optic nerve 
crush in Sprague Dawley (SD) rats (Biermann et al., 2011) and after retinal 
ischemia in Wistar rats (Zhang et al., 2011). Moreover, VPA alone or in 
combination with guanabenz and a caspase-12 inhibitor increased the ONL 
thickness and preserved photoreceptor function in a Bardet Biedl syndrome 
mouse model (BBS12-/-) (Mockel et al., 2012).  
 
Additionally, VPA was reported to be protective in the P23H Xenopus model 
(Vent-Schmidt et al., 2017); however, there was no improvement in mutant 
rhodopsin trafficking, something that had been previously suggested as being 
VPA’s mode of action (Clemson et al., 2011). Instead, there was a reduction 
in global levels of rhodopsin, suggesting enhanced rhodopsin degradation, as 
previously seen after dark rearing in the same model (Tam and Moritz, 2007), 
and the effect was mediated by HDAC inhibition (Vent-Schmidt et al., 2017). 
Interestingly, the same doses that were protective in the P23H model 
exacerbated retinal degeneration in the T17M model of RP, where light, as 
opposed to misfolding, is more important for cell death. Although the effect 
was mediated by HDAC inhibition, the mechanism of T17M exacerbation 
remains unclear as VPA did not interfere with rhodopsin degradation or 
trafficking. VPA also exacerbated retinal degeneration in Xenopus S344ter 
and T4K models (Vent-Schmidt et al., 2017). Therefore, the effect of VPA was 
dependent by both genotype and environmental conditions. The study of 
Vent-Schmidt et al. (2017) was not the only one that showed opposing effects 
of VPA in different retinal degeneration models. VPA treatment significantly 
reduced photoreceptor loss in the fast-degenerative rd1 mouse model by P20, 
but accelerated degeneration in the slow-degenerative rd10 model, even 
though both are caused by mutations in PDE (PDE6) (Mitton et al., 2014). The 
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authors also reported that VPA can cause photoreceptor loss in the immature 
retina, since they observed reduced ONL thickness in WT mice when 
administered at P9 but not at P17 (Mitton et al., 2014).  
 
We tested VPA in the P23H-1 rat model by providing it in drinking water from 
postnatal (P) day P21 to P35. Interestingly, we observed that VPA treatment 
decreased photoreceptor function and survival, as the VPA-treated rats 
showed significantly lower a-waves and thinner ONL compared to the vehicle-
treated rats (Figure 6), suggesting that VPA is detrimental for this model of 
RP, which is the opposite of what was observed in the P23H Xenopus model 
(Vent-Schmidt et al., 2017).  
 
A published report of off-label VPA use for the treatment of RP (Clemson et 
al., 2011) was used as the basis for establishing a clinical trial in the USA, but 
this report has attracted a lot of controversy. This was due to the use of non-
genotyped patients, low numbers, the short duration, the study design, 
statistical analysis and lack of reporting any side effects (Sandberg et al., 
2011; Sisk, 2012; van Schooneveld et al., 2011). In another study, short-term 
treatment with oral VPA for three months in 10 patients with established RP 
showed improvement in visual acuity and vision (Shanmugam et al., 2012). 
Similarly, other studies followed which tested the efficacy of VPA in RP 
patients for up to 6 or 12 months and reported some positive effect to visual 
function of patients (Iraha et al., 2016; Kumar et al., 2014); however, all the 
aforementioned studies had similar limitations with the Clemson et al. study. A 
longer follow up of patients (up to 4 years) with several retinal dystrophies, 
including a total of 31 patients (21 RP patients and some from the Clemson et 
al., study) showed no benefit of VPA treatment and secession of treatment in 
30% of the patients due to adverse effects of the drug (Bhalla et al., 2013). 
Additionally, epileptic patients can develop colour vision defects after VPA 
treatment (Verrotti et al., 2004), questioning further the clinical utility of VPA 
for visual problems. Collectively, these studies raise several concerns about 
the efficacy of VPA, highlight the importance of taking into account the 
specific genetic defects and potential differences between mutations before 
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conducting a clinical trial and suggest that VPA cannot be used 
indiscriminately for the treatment of RP.  
 
5.3 Nutritional supplements - Vitamin A palmitate 
Vitamin A palmitate alone, or in combination with docosahexaenoic acid 
(DHA) and lutein, are the only prescribed treatments for RP; however, there is 
an ongoing debate in the scientific community for their efficacy to slow down 
the course of the disease.  In 1993, Berson et al. investigated the effect of 
15,000 IU/d supplementation of vitamin A and/or 400 IU/d of vitamin E and 
trace amounts of both vitamins, in 601 randomised patients with RP for up to 
6 years and the results were assessed by performing 30 Hz cone flicker ERG. 
They reported a protective effect of vitamin A at high doses and a detrimental 
effect of vitamin E (Berson et al., 1993). Later, in 2004, the same group 
showed that the addition of DHA capsules to high dose (15,000 IU/d) vitamin 
A supplementation did not slow the course of the disease (Berson et al., 
2004a); however, in a parallel study, DHA was protective in the first two out of 
four years in patients who did not take any vitamin A before the study (Berson 
et al., 2004b). In a third trial, Berson et al. (2010) tested the addition of 12 
mg/day lutein to high dose of vitamin A (15,000 IU/d) and concluded that this 
combination with a high fish oil diet, where DHA is a major component, could 
benefit RP patients (Berson et al., 2010). Despite their positive outcomes, all 
the aforementioned studies have been criticised: for the methodology and 
statistical analysis; the robustness of the data, as there were no significant 
benefits in any measure of visual function; and that conclusions were drawn 
based on secondary outcomes and not primary outcome measures (Marmor, 
1993; Massof and Finkelstein, 1993; Massof and Fishman, 2010; Norton, 
1993).  
 
Perhaps more importantly, these studies were not conducted in genotyped 
patients and there is growing evidence that vitamin A should be avoided in 
some IRD patients. For example, patients that have mutations in the 
Stargardt’s disease gene ABCA4, which can also cause arRP, are vulnerable 
to high levels of vitamin A (Charbel Issa et al., 2015). High doses of vitamin A 
could also cause liver damage and could cause severe birth defects if taken 
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during pregnancy (Massof and Fishman, 2010). Interestingly, vitamin A 
deprivation prevented light-induced retinal degeneration in transgenic X. 
laevis expressing T4K opsin, suggesting that vitamin A supplementation could 
be detrimental to patients that carry the T4K rhodopsin mutation and patients 
that have sector RP (Tam et al., 2014). 
 
In contrast, supplementation of vitamin A decreased the rate of retinal 
degeneration in the mouse T17M RP model, however, it had no effect in the 
P347S model (Li et al., 1998a). These data could support the hypothesis that 
increased levels of vitamin A could act as a pharmacological chaperone to 
promote mutant rhodopsin folding. Vitamin A deprivation also induced retinal 
degeneration in a P23H Xenopus model, reiterating the importance of vitamin 
A for retinal homeostasis (Tam et al., 2010a); however, evidence from Rpe65 
polymorphisms in mice suggests that excess 11-cis-retinal may exacerbate 
P23H mutant opsin disease progression (Samardzija et al., 2006a). The 
Rpe65 polymorphism that has increased RPE65 activity, and presumably 
higher 11-cis-retinal levels, were associated with faster degeneration in the 
P23H mice, thereby illustrating how genetic modifiers could influence the 
progression of rhodopsin adRP. One of the limitations for the use of vitamin A 
is that 11-cis-retinal is produced efficiently via the visual cycle in the retina 
and therefore is more than adequate in most young individuals with a healthy 
diet. Increasing the amount of retinoid availability combined with light 
exposure could result in unnaturally high levels of all-trans retinal, which is 
toxic to photoreceptors (Chen et al., 2012). Their use as pharmacological 
chaperones is also limited as cis-retinoids change conformation when 
bleached, and because locked forms do not discriminate between opsins, 
they could potentially affect cone opsin function. Therefore, similar to VPA, 
vitamin A supplementation needs to be carefully considered and cannot be 
given broadly to RP patients, regardless of genetic diagnosis.  
 
5.4 Prolonging cell survival with cell death inhibitors or neurotrophic 
factors 
Cell death pathways can also be targeted for the treatment of rhodopsin RP. 
For instance, cone survival, together with preservation of ONL thickness and 
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improvement of rod function was observed after treatment of the P23H-1 rat 
model with the cell death inhibitors necrostatin-1s (RIP1 inhibitor) and N-
acetylcysteine (an inhibitor of NLRP3), while calpeptin (calpain inhibitor) 
improved only rod function and survival, but did not affect cones 
(Viringipurampeer et al., 2016). 
 
Ablation of caspase-1 preserved retinal morphology and increased rhodopsin 
expression in the VPP/GHL (P23H) mouse (Table 4), but not in rd1 and light-
induced retinal degeneration models, where caspase-1 is also abnormally 
overexpressed. The protection in this rhodopsin mouse model was only 
transient, however, providing more evidence that additional pathways, 
independent of caspase-1 are also involved in photoreceptor death process 
(Samardzija et al., 2006b). In addition, ablation of caspase-7 in T17M 
rhodopsin mice preserved retinal structure and function even from light-
induced damage and it was suggested this was mediated by reducing ATF6 
and PERK signalling and reducing JNK-induced apoptosis (Choudhury et al., 
2013).  Finally, viral delivery of the X-linked inhibitor of apoptosis (XIAP), 
which inhibits the action of caspases-3, -7 and -9 preserved both 
photoreceptor structure and function in the P23H-1 model, but protected only 
photoreceptor structure in the S334ter rhodopsin model highlighting that the 
different nature of rhodopsin mutations can affect the protection offered by 
targeting common apoptotic pathways (Leonard et al., 2007).  
 
Another way to protect the degenerating retina in rhodopsin RP is to provide 
neuroprotection through supplementation with neurotrophic factors. The 
advantage of neurotrophic factors is that they can potentially improve vision 
for a range of retinal disorders, as they act on neuronal survival irrespective of 
the genetic cause. Ciliary neurotrophic factor (CNTF) is the most extensively 
studied factor both preclinically in different models of retinal degeneration, and 
in the clinic. Viral-mediated delivery of CNTF in the Rho KO mouse model led 
to a significant increase in photoreceptor survival up to 3 months (Liang et al., 
2001), while recombinant intravitreal delivery in the S334ter rat model led to 
increased cone survival through the preservation of cone OS (Li et al., 2010). 
CNTF supplementation in the peripherin 2 mouse model (Prph2rd2/rd2), 
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however, led to rod photoreceptor dysfunction (Schlichtenbrede et al., 2003). 
A recent clinical report on a long-term follow up of RP patients that received 
implant-mediated CNTF supplementation found no serious adverse effects, 
but also no evidence of efficacy or improved retinal structure and visual 
function (Birch et al., 2016). Transgenic mediated overexpression of brain 
derived neurotrophic factor (BDNF) provided structural and functional rescue 
in the presence of Q334ter rhodopsin (Okoye et al., 2003). Overexpression of 
glial-derived neurotrophic factor (GDNF) using adeno-associated virus (AAV) 
vectors was also shown to provide structural and functional rescue in both the 
S334ter rat (Dalkara et al., 2011) and in other models of retinal degeneration 
such as the Prph2rd2/rd2 and in the Royal College of Surgeons (RCS) rat (Buch 
et al., 2006). More recently, viral-mediated erythropoietin supplementation in 
the P23H transgenic mouse led to a structural and functional rescue that 
persisted for 7 months (Rex et al., 2016).  
 
Furthermore, subretinal injections of the Rod-derived Cone Viability Factor 
(RdCVF) preserved cone photoreceptor numbers and photopic function in 
P23H-1 rats (Yang et al., 2009), while systemic viral delivery to neonates and 
intravitreal viral administration of RdCVF rescued both the structure and 
function of cone photoreceptors in the rd10 and P23H KI mouse models 
(Byrne et al., 2015). Interestingly, AAV-mediated delivery of the longer 
counterpart RdCVFL early in the disease did not rescue cone cells, but 
improved rod function, increased levels of rhodopsin, and decreased the by-
products of cellular oxidative stress in dark reared rd10 animals (Byrne et al., 
2015). It remains to be seen if clinical application of any of these neurotrophic 
factors will replicate their preclinical efficacy without deleterious effects. 
 
5.4 Genetic modification strategies 
 
5.4.1 RNA interference, ribozymes and antisense oligonucleotides  
Initial gene therapy approaches to treat dominant RP in animal models have 
involved knockdown of the mutant allele or complete suppression of all 
rhodopsin followed by supplementation with a rhodopsin cDNA resistant to the 
silencing agent. The first proof of concept involved AAV-mediated delivery of 
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a ribozyme targeting the P23H allele which provided functional and structural 
rescue in the P23H transgenic rat for up to 8 months (LaVail et al., 2000). 
Ribozymes are difficult to design, however, and not suitable for all variants. 
Indeed, the P23H allele in this rat model was adapted to be optimal for 
ribozyme cleavage (Orhan et al., 2015).  
 
In contrast, allele specific targeting by antisense oligonucleotides targeting the 
P23H allele in the P23H-1 rat model showed some functional rescue a month 
following intravitreal administration (Murray et al., 2015b). Furthermore, allele 
independent RNA interference applications have demonstrated rhodopsin 
reductions of up to 90% with subsequent supplementation of a resistant WT 
allele that can rescue the P23H mouse for up to 9 months, and the P347S 
mouse for up to 10 weeks (Chadderton et al., 2009; O'Reilly et al., 2007).  
 
More recently, a different AAV-based approach to silence mutant rhodopsin 
expression utilised engineered proteins that bind cis-acting elements 
upstream of the rhodopsin gene, reducing its expression (Botta et al., 2016). 
Their efficiency to target rhodopsin mutations was shown in the P347S mouse 
where a functional improvement was seen two weeks post-treatment and also 
in the porcine retina, where total rhodopsin knockdown was followed by 
supplementation with human rhodopsin (Botta et al., 2016). 
 
5.4.2 Gene therapy 
Gene supplementation is an option to treat recessive disorders where the 
target gene product is lacking, but is less certain in dominant disease with a 
clear gain of function effect, as opposed to haploinsufficiency. Surprisingly, 
gene supplementation with WT rhodopsin was shown to provide protection 
from cell death in the P23H mouse (Mao et al., 2011). In this study, WT 
rhodopsin overexpression in the mutant mice improved retinal structure and 
function up to 6 months post-treatment, indicating that overexpression could 
provide benefit. These data provide further evidence for a dominant negative 
effect of class 2 mutants and the protective potential of the WT allele. In the 
same study, however, it was noted that rhodopsin overexpression in WT mice 
caused retinal degeneration, indicating that the rhodopsin level is critical and 
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needs to be carefully controlled as it has a protective effect only in the 
presence of a dominant mutant and across a small window of rhodopsin 
expression.  
 
Additionally, gene augmentation with protective factors can also provide 
protection against cell death. For example, P23H rats that received AAV-
mediated delivery of proinsulin, which has been characterised as a 
neuroprotective molecule, had functional rescue for up to 4 months 
(Fernandez-Sanchez et al., 2012), indicating that certain types of gene 
augmentation might be applicable to ameliorate adRP phenotype. 
 
5.4.3 CRISPR/Cas9 
CRISPR/Cas9 technology is at the forefront of gene editing research 
attracting much attention because of its efficiency and stringency in genomic 
targeting and due to its simplicity to design a guiding molecule directing the 
nuclease at the locus of interest. CRISPR/Cas9 applications rely on either the 
inactivation of the cleaved genomic locus following non-homologous end 
joining (NHEJ) or its precise correction following homology directed repair 
(HDR). In the post-mitotic retina HDR is very inefficient; therefore, most 
applications focusing on targeting mutant alleles have aimed to render them 
inactive using NHEJ. As CRISPR/Cas9 is still at early stages for in vivo 
applications, there are only a few studies investigating its use to treat 
rhodopsin-mediated RP. For instance, an innovative study by Yu et al., (2017)  
used AAV-mediated CRISPR/Cas9 inactivation of Nrl, a rod-specific 
transcription factor, to alter rod cell fate determination in the rd10, Rho KO 
and P347S Rhodopsin mouse models and reported improvement of rod 
survival and preservation of cone function. 
 
In a rhodopsin targeted approach, electroporation of a plasmid encoding for a 
Cas9 nuclease and a guide RNA (gRNA) targeting the P23H allele into mouse 
retina showed a marked reduction in expression of P23H on a rhodopsin null 
background (Latella et al., 2016). In this study, in addition to the reduced 
levels of P23H, a high proportion of genomic editing was reported (up to 
33%). It is important to note that as electroporation efficiency in the retina is 
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low, the analyses were performed in the GFP selected cells that had received 
the CRISPR/Cas9 plasmid (as visualised by reporter gene expression) and 
not in whole retinal lysates. More recently, a similar approach was used to 
target the P23H allele as well as an HDR-mediated correction in vitro in iPS 
cells, followed by in vivo NHEJ-mediated targeting in the pig retina (Burnight 
et al., 2017). 
 
Moreover, Bakondi et al. (2016)  used a similar approach to target the S334ter 
allele in transgenic rats and they reported an improvement in function 
following electroporation of the targeting plasmid. This exciting technology, 
however, is still in its infancy and faces significant technical challenges and 
more broadly applicable approaches. For example, in the case of rhodopsin 
adRP, any CRISPR approach must be allele specific or it would convert an 
adRP phenotype to a more severe arRP one, and these studies have not 
been done on human rhodopsin genomic sequences in the context of one 
mutant and one WT allele. Furthermore, a recent study of CRISPR/Cas9 
targeting in fertilized Xenopus eggs showed that in-frame deletions frequently 
caused dominant retinal degeneration associated with rhodopsin biosynthesis 
defects, while frameshift phenotypes were consistent with knockout (Feehan 
et al., 2017). Given that NHEJ is random, there is almost a 1:3 chance that 
CRISPR gene editing could replace one dominant rhodopsin mutation with 
another dominant mutation within individual rods, even if the editing were 
allele specific.  
 
Furthermore, while all the above studies do not report any off-target effects 
and several studies suggested a low incidence of off-target mutations using 
CRISPR/Cas9 (Iyer et al., 2015; Smith et al., 2014; Veres et al., 2014), a 
recent study reported multiple unexpected off-target effects after using 
CRISPR/Cas9 in vivo (Schaefer et al., 2017). However, several concerns 
have been raised in the scientific community regarding the interpretation of 
the data, the low numbers of animals and the overall experimental design of 
this study and support the hypothesis that these off target effects are due to 
genetic variation between the animals studied and not due to CRISPR/Cas9 
treatment (Kim et al., 2017; Lareau et al., 2017; Wilson et al., 2017). 
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Nevertheless, improving CRISPR specificity and efficacy is important because 
even a low frequency of unexpected mutations can be harmful and any 
potential off target effects should be considered and tested in more detail 
before any clinical application (Tasan and Zhao, 2017).   
 
6. Concluding remarks 
Immense progress has been made in the understanding of molecular 
pathways that lead to retinal degeneration associated with rhodopsin 
mutations. Conflicting therapeutic outcomes from different animal models 
reflect the complexity of this type of retinal degeneration. They also highlight 
the importance of understanding the molecular consequences of the many 
different types of mutation and developing mutation mechanism-dependent 
therapeutic strategies, regardless of whether these are dealing with the cause 
of the disease or the consequences of the disease. These approaches are 
getting closer to the clinic and the enhanced understanding of rhodopsin 
function informs, not only GPCR biology, but also more efficient patient-
tailored therapies. 
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Tables.  
Table 1. Classification of adRP and adCSNB mutations. Classification of 
rhodopsin mutations described in HGMD (http://www.hgmd.cf.ac.uk/) based 
on their experimentally studied biochemical and cellular characteristics. 
Italicised substitutions are observed in the gnomAD dataset at a frequency of 
~ 1:80,000 or more and might be non-pathogenic substitutions. § might 
behave as class 4 after 11-cis-retinal rescue. † might behave as class 2 on 
overexpression, but class 4 in vivo.  
 
Classification Key features Mutations 
1 Post Golgi trafficking 
and OS targeting 
L328P, T342M, Q344R/P/ter, V345L/M, 
A346P, P347A/R/Q/L/S/T, ter349/Q/E 
2 
Misfolding, ER 
retention and 
instability  
N15S§, T17M†, V20G§, P23A/H/L§, 
Q28H§, G51R/V, P53R, T58R/M, V87D, 
G89D, G106R/W, C110F/R/S/Y, E113K, 
L125R, W161R, A164E/V, C167R/W, 
P171Q/L/S, Y178N/D/C, E181K, 
G182S/V, C185R, C187G/Y, G188R/E, 
D190N/G/Y, H211R/P, C222R, P267R/L, 
S270R, K296N/E/M 
3 
Disrupted vesicular 
traffic and 
endocytosis 
R135G/L/P/W 
4 
Altered post-
translational 
modifications and 
reduced stability 
T4K†, T17M†, M39R, N55K, G90V 
5 Altered transducin 
activation M44T, V137M 
6 Constitutive activation G90D, T94I, A292E, A295V 
7 Dimerization deficiency  F45L, V209M, F220C 
Unclassified 
No observed 
biochemical or 
cellular defect or not 
studied in detail 
P12R, R21C, Q28H, L40R, L46R, L47R, 
F52Y, F56Y, L57R, Y60ter, Q64ter, 
R69H, N78I, L79P, V87L, L88P, T92I, 
T97I, V104F, G109R, G114D/V, E122G, 
W126L/ter, S127F, L131P, Y136ter, 
C140S, T160T, M163T, A169P, 
P170H/R, S176F, P180A/S, Q184P, 
S186P/W, Y191C, T193M, M207R/K, 
V210F, I214N, P215L/T, M216R/L/K, 
R252P, T289P, S297R, A298D, K311E, 
N315ter, E341K, S343C 
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Table 2. RHO mutations associated with an arRP phenotype. 
 
Mutation Notes References 
E150K Found in consanguineous Indian, 
Pakistani and Turkish families1-4. 
Heterozygous carriers appear normal2. 
Knock-in mouse model suggests mild 
dominant mutation5. 
1Kumaramanickavel 
et al., (1994)  
2Azam et al., (2009)  
3Saqib et al., (2015)  
4Van Schil et al., 
(2016)  
5Zhang et al. (2013) 
W161ter Found in non-consanguineous 
Indonesian families - heterozygous 
carriers appear normal6. Mutant 
transcript subject clearance by 
nonsense-mediated decay (NMD)7. 
6Kartasasmita et al., 
(2010) 
7Roman-Sanchez et al., 
(2016) 
E249ter Found in consanguineous French-
Canadian family8. Asymptomatic 
heterozygous carriers show slightly 
depressed ERGs9. Mutant transcript 
subject to clearance by nonsense-
mediated decay (NMD)7,10. 
8Rosenfeld et al., 
(1992) 
9Rosenfeld et al., 
(1995)  
10Hernan et al., (2011) 
M253I Found in patient of consanguineous 
Turkish descent - heterozygous parents 
were asymptomatic11. M253I was found 
in the heterozygous state in 5 out of 35 
LCA patients in Canadian study12. 
11Collin et al., (2011)  
12Mezer et al., (2006)  
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Table 3. Clinical classification of rhodopsin RP mutations. Class A 
phenotype refers to a severe early-onset loss of rod function. Class B refers to 
a milder phenotype, with retained rod function at least in certain retinal 
regions.  
 
Phenotype Mutation Reference 
Class A L88P1, L131P1, R135L/G/W2, 
E181K2, Q344P1, V345L2, 
P347L2 
1Audo et al., (2010)  
2Cideciyan et al., (1998) 
3Iannaccone et al., (2006) 
Class B N15S1, T17M2, P23H2, T58R2, 
Q64ter2, V87D2, G89D2, G106R2, 
P180A3, G188R3, D190G/Y2, 
T193M2, M207K2, Q312ter2, 
T342M2, Q344ter2 
1Audo et al., (2010)  
2Cideciyan et al., (1998) 
3Iannaccone et al., (2006) 
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Table 4: Commonly used mammalian models of rhodopsin RP (KO = knock-
out; KI = knock-in; Tg = transgenic). 
 
 
 
Mutation Species Methodology Reference(s) 
Rho KO Mouse Homologous 
recombination 
Humphries et al., (1997) 
Lem et al., (1999)   
T4R Dog Spontaneous Kijas et al (2002)  
T17M (Tg) Mouse Human Transgene Li et al (1998)  
V20G-P23H-P27L 
(VPP) (Tg) 
Mouse 
 
Mouse Transgene Naash et al., (1993)  
P23H (Tg) Mouse Human Transgene (Olsson et al., 1992) 
P23H (KI) Mouse Homologous 
recombination 
Sakami et al., (2011)  
P23H-GFP (KI) Mouse RHO-GFP 
Homologous 
Recombination 
Price et al., (2011) 
P23H (Tg) Rat 
P23H Line 1 (P23H-1) 
P23H Line 2 (P23H-2) 
P23H Line 3 (P23H-3) 
Mouse Transgene 
(1 high copy=fast) 
(3=slow) 
Pennesi et al., (2008) 
P23H (Tg) Pig Human Transgene Ross et al., (2011)   
G90D (Tg) Mouse Mouse Transgene Sieving et al., (2001) 
E150K (KI) Mouse Homologous 
recombination 
Zhang et al (2013)  
S334ter (Tg) Rat 
S334ter Line 3 (S334ter-3) 
S334ter Line 4 (S334ter-4) 
S334ter Line 5 (S334ter-5) 
S334ter Line 7 (S334ter-7) 
S334ter Line 9 (S334ter-9) 
Mouse Transgene Pennesi et al., (2008) 
Q344ter (Tg) Mouse Mouse Transgene Sung et al., (1994) 
P347L (Tg) Rabbit Rabbit Transgene Kondo et al., (2009) 
P347L (Tg) 
 
Pig Pig Transgene Petters et al., (1997) 
P347S (Tg) Mouse Human Transgene Li et al., (1996) 
P347S (Tg) Pig Pig Transgene Kraft et al., (2005) 
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Figure legends 
 
Figure 1. The structure of rhodopsin. The tertiary structure of bovine 
rhodopsin from the intradiscal N-terminus (dark blue) to the cytoplasmic C-
terminus (red) containing 7 transmembrane motifs (ɑ-helix I-VII) and 
cytosplamic helix VIII shown in a 3D model. 11-cis retinal (black), T4, P23, 
E113, R135, K296 and the disulphide bond site C110-C187 are highlighted. 
The 3D image was made using PyMol (PDB 1U19).  
 
Figure 2. The position of rhodopsin mutations. The primary amino acid 
sequence of human rhodopsin is shown as a secondary structure schematic 
to show the position of different classes of mutation. Class 1, post-Golgi 
trafficking and outer segment targeting (blue). Class 2 misfolding, ER 
retention and instability (green). Class 3, disrupted vesicular trafficking and 
endocytosis (violet). Class 4, altered post-translational modifications and 
reduced stability (yellow). Class 5 altered transducin activation (pink). Class 6 
constitutive activation (brown). Class 7 dimerization deficiency (orange). 
Where there is evidence for more than one type of class it is shown with a 
vertical colour split. Uncategorised mutations, or those with no biochemical or 
cellular defects are shown in grey. Those with predicted effects on folding or 
binding from FoldX (Rakoczy et al., 2011) are shown with a horizontal colour 
split. The 8 alpha helix motifs of rhodopsin are highlighted by blue boxes.  
 
Figure 3. Schematic illustration of the potential pathogenic 
consequences caused by rhodopsin mutations. A rod photoreceptor has 
distinct regions; including, the outer segments (OS) and inner segments (IS), 
cell body and synaptic terminals. Pathogenic mutations in rhodopsin disturb 
several cellular pathways, including endocytosis dysfunction, structural 
instability of the OS, mistrafficking, and misfolding. Top left, class 3, 
hyperphosyphorylated rhodopsin is bound by arrestin (green), the Rho-
arrestin complex is endocytosed and disrupts vesicular traffic. Top right, upon 
illumination, unstable rhodopsin mutants (class 2, 4 and 7) could aggregate in 
the disk of OS, thus causing damage of the plasma membrane homeostasis. 
Bottom left, class 1 mutations that affect the ciliary targeting signal, VXPX, are 
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mislocalised, including at the synapse, where they could inhibit synaptic 
vesicle fusion or be abnormally activate transducin. Misfolding class 2 
rhodopsin mutants in the ER might induce ER stress, degraded by ERAD and 
potentially aggregate, leading to the activation of pro-apoptotic pathways.  
 
Figure 4. 4-PBA does not affect photoreceptor function and survival in 
P23H-1 rats. P23H-1 rats were either left untreated or treated from P21 to 
P49 with 400 mg/kg 4-PBA (n = 4 for each condition) via IP injection. (A) 
Scotopic ERG’s were performed as previously described (Aguila et al., 2014). 
No significant differences were observed in P23H-1 rats that had received the 
treatment at any time point and at any intensity (-6 to 2.7 log cds/m2) (data not 
shown). Average at 0 log cds/m2 for a-wave and b-wave of P23H-1 rats at 3, 5 
and 7 weeks of age. Values are means ± SEM. n.s non-significant values, 2 
way ANOVA. (B) Retinal histology for measuring the outer nuclear layer 
(ONL) thickness was made on digital images of stained cryosections, every 
500 microns from the optic nerve outwards for both the inferior and superior 
hemisphere. The ONL thickness across the whole from 4 animals at each 
time point was averaged and analysed using Graphpad Prism (Sigmastat). 
(C) Representative images of the ONL in treated and untreated P23H-1 rats 
at 3. 5 and 7 weeks stained with DAPI (blue), anti-rhodopsin antibody 1D4 
(green) and cone marker peanut agglutinin (PNA) (red). Scale bar = 50 
microns. 
 
Figure 5. TUDCA improves photoreceptor function and survival in P23H-
1 rats but has no effect in P23H KI mice. P23H-1 rats were received 500 
mg/kg TUDCA (n=9) or vehicle-PBS (n=7) from P21-P35 and P23H KI mice 
were received 500 mg/kg TUDCA (n=8) or vehicle-PBS (n=7) from P21-P43.  
(A, C) Scotopic ERG’s were performed as previously described (Athanasiou 
et al., 2017) at -5 to 1-log intensities (data not shown). (A) Average at 0 log 
cds/m2 for a-wave and b-wave of P23H-1 rats showing significant 
improvement of a-wave in TUDCA-treated compared to vehicle-treated P23H-
1 rats (*p<0.05). The b-wave is not significantly affected (n.s) by TUDCA 
treatment. (B, D) OCT analysis was performed as previously described across 
the nasal-temporal meridian (Athanasiou et al., 2017a). The mean ONL 
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thickness across the whole retina is significantly enhanced in TUDCA-treated 
P23H-1 rats (**p<0.01). (C) Average at 0 log cds/m2 for a-wave and b-wave of 
P23H-KI mice showing no significant changes in both the a-wave and b-wave 
in TUDCA-treated compared to vehicle-treated P23H-KI mice (n.s). (D) The 
mean ONL thickness across the whole retina does not alter in TUDCA-treated 
mice (n.s). (A-D) Values are mean ± SEM. Unpaired two-sided Student's t 
test.  
 
Figure 6. Valproic acid worsens photoreceptor function and survival in 
P23H-1 rats. P23H-1 rats were received VPA (7.1 gm/Liter) in drinking water 
(n=9) or water (n=8) from P21-P35. (A) Scotopic ERG’s were performed as 
previously described (Athanasiou et al., 2017a) at -5 to 1-log intensities (data 
not shown). Average at 0 log cds/m2 for a-wave and b-wave of P23H-1 rats 
showing significant reduction of a-wave in VPA-treated animals (**p<0.01). 
The b-wave is not significantly affected (n.s) by VPA treatment. Values are 
mean ± SEM. Unpaired two-sided Student's t test. (B) OCT analysis was 
performed as previously described (Athanasiou et al., 2017) across the nasal-
temporal meridian. The mean ONL thickness across the whole retina is 
significantly reduced in VPA-treated animals (**p<0.001). Values are mean ± 
SEM. Unpaired two-sided Student's t test.   
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